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ABSTRACT 
Staphylococcus aureus and group A Streptococcus express a family of exotoxins including 
staphylococcal enterotoxins A, B, C (SEA, SEB, SEC), toxic shock syndrome toxin-1 (TSST-1) 
and streptococcal pyrogenic exotoxins (SpeA, SpeC) that possess superantigenic properties, by 
virtue of which they stimulate a large fraction of an individual’s T cells, leading to 
hyperinflammation and in some cases, organ failure and death. The molecular mechanism behind 
hyperinflammation has been attributed to the binding of superantigen (SAg) to both a T cell 
receptor (TCR) on a T cell, and a class II product of the major histocompatibility complex (MHC) 
on an antigen presenting cell, which leads to cross-linking of cells and excessive cytokine release 
from both cell types. Although SAgs bind with low affinity to the variable region of the beta chain 
(Vβ) of the TCR, they are very potent toxins. These toxins have been incriminated in food 
poisoning, sepsis, toxic shock syndrome (TSS), infective endocarditis, and skin conditions like 
atopic dermatitis. For purposes of neutralizing or detecting SAg, soluble versions of several Vβ 
domains against various SAgs have been engineered in the Kranz laboratory. Yeast display and 
directed evolution have allowed development of soluble, high-affinity Vβ proteins some of which 
have also been successfully used in animal models of S. aureus infections. In this work, a high-
affinity Vβ receptor for Staphylococcal enterotoxin A (SEA) was generated, and the use of this 
and other engineered, high-affinity Vβ proteins as specific and sensitive detecting agents was 
explored.  
SEA is one among the collection of enterotoxins secreted by Staphylococcus aureus, 
which acts as a superantigen. It is also the most common enterotoxin recovered from food 
poisoning outbreaks in the United States. It is estimated that in most cases, the dose of SEA that 
causes the disease is of the order of a few micrograms per individual. In this study, I engineered 
a soluble form of a Vβ that had high affinity toward SEA, for purposes of understanding its 
molecular interaction with SEA and also to develop specific, sensitive assays for detection of SEA. 
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In chapter 2, the process of engineering of human Vβ22 protein for improving its affinity 
towards SEA is described. In this chapter, yeast display coupled with random mutagenesis and 
fluorescence-activated cell sorting (FACS) was used to select for stably expressing Vβ22 mutants 
on yeast cell surface. Because the affinity of stabilized Vβ22 mutants for SEA was low, these 
were then subjected to directed mutagenesis to select for mutants with enhanced affinity towards 
SEA. Incorporation of additional mutations by site-directed mutagenesis, yielded the high affinity 
mutant called “FL”. Selected Vβ22 mutants were expressed in E.coli and refolded in vitro, for 
assessing their binding properties. In collaboration with Dr. Eric Sundberg, the binding constants 
for interaction of wt Vβ22 and high affinity “FL” protein with SEA were determined by surface 
plasmon resonance. FL protein was shown to bind SEA with a KD value of 4nM, which was a 
25,000-fold improvement in affinity compared to the wild-type protein, which binds SEA with low 
affinity (KD ~100µM). The SEA:Vβ interface was centered around residues within the 
complementarity determining region 2 (CDR2) loop of the Vβ. The engineered, high-affinity Vβ22 
protein was specific for SEA, in that it did not bind to two other closely related enterotoxins SEE 
or SED, providing information on the SEA residues possibly involved in the interaction. Finally, 
the high-affinity Vβ22 mutant protein was used for development of a capture-ELISA based 
platform for specific detection of SEA. 
In Chapter 3, a bead-based, two-color flow cytometry approach was used to develop a 
multiplex assay for simultaneous detection of staphylococcal (SEA, SEB and TSST-1) and 
streptococcal (SpeA and SpeC) toxins in a single sample. Vβ domains that were engineered for 
for binding with high-affinity to these toxins were used together with commercial, polyclonal, anti-
toxin reagents to enable specific and sensitive detection with SD50 values of 400 pg/ml (SEA), 3 
pg/ml (SEB), 25 pg/ml (TSST-1), 6 ng/ml (SpeA), and 100 pg/ml (SpeC) in singleplex assays. 
These sensitivities were in the range of 4- to 80-fold higher than achieved with standard ELISAs 
using the same reagents. The singleplex assays were combined to yield a multiplex assay that 
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allowed reliable detection of the toxins in a single sample. In multiplex format, the sensitivity of 
detecting individual toxin was reduced due to higher noise associated with the use of multiple 
polyclonal agents, but the sensitivities were still well within the range necessary for detection in 
food sources or for rapid detection of toxins in culture supernatants. For example, the assay 
specifically detected SEA, SEB and TSST-1 in supernatants derived from cultures of various 
strains of Staphylococcus aureus. Thus, these reagents and the flow cytometry-based platform 
can be used for simultaneous detection of the toxins in food sources or culture supernatants of 
potential pathogenic strains of Staphylococcus aureus and Streptococcus pyogenes, or directly 
in clinical samples.  
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CHAPTER ONE 
ENGINEERING SOLUBLE T CELL RECEPTOR DOMAINS FOR HIGH-AFFINITY BINDING 
TO STAPHYLOCOCCAL AND STREPTOCOCCAL SUPERANTIGENS1 
 
Staphylococcal and streptococcal superantigens 
Over the past 30 years, the family of exotoxins expressed by Staphylococcus aureus and 
group A Streptococcus known as “superantigens” (SAgs) [1] has been studied extensively at the 
molecular and structural levels. These toxins are referred as superantigens because they 
stimulate a large fraction of an individual’s T cells. One consequence of this hyperactivity is 
massive cytokine release leading to severe tissue inflammation and, in some cases, systemic 
organ failure and death. The molecular basis of action of SAg involves its binding to both the 
variable region of the beta chain (Vβ) of a T cell receptor (TCR) on a T cell and a class II product 
of the major histocompatibility complex (MHC) on an antigen presenting cell. This cross-linking 
leads to aggregation of the TCR complex that initiates downstream signaling resulting in massive 
release of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interferon-γ (IFN-
γ), and interleukin (IL-2), into the circulation or tissues. A common feature of SAgs is that they 
bind with relatively low affinity to the variable region of the beta chain (Vβ) of the TCR. Despite 
this low affinity binding, SAgs are very potent, as each T cell requires only a small fraction of their 
receptors to be bound in order to trigger cytokine release. 
There are 24 SAgs known to be expressed by S. aureus and 11 SAgs known to be 
expressed by group A Streptococcus [2-5]. Despite their sequence diversity, these toxins exhibit 
a canonical structural motif that consists of two domains, a smaller N-terminal domain with two β-
sheets and a larger C-terminal domain with a central α-helix and a five-stranded β-sheet [5-8]. 
                                               
1 This chapter is adapted from a review article published in Toxins journal as: Sharma P., Wang N., and Kranz D.M. 
(2014) “Soluble T cell receptor Vβ domains engineered for high-affinity binding to staphylococcal or streptococcal 
superantigens.”, Toxins (Basel), 6(2):556-74.  
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This canonical structure has presumably allowed SAgs to maintain their ability to interact with a 
T cell receptor Vβ domain on one side of the molecule and a class II product of the MHC on another 
side [6]. This dual binding is required for activation of T cells and subsequent cytokine release, as 
monovalent binding of a ligand to the TCR is not sufficient for signaling. SAg-mediated crosslinking 
with MHC allows multiple MHC-bound SAg molecules to form a multivalent TCR complex, thereby 
initiating signaling [6, 9, 10].  
The pathogenic function of SAgs is not clear, although it is likely related to their ability to 
dysregulate an immune response, or perhaps to generate a cytokine milieu that is favorable for 
survival of the organism. While the precise functional or evolutionary advantage of expressing a 
large family of SAgs with extensive sequence diversity is unclear, one clinical consequence has 
been that antibodies generated against one of the SAgs are not likely to cross-react with most of 
the other SAgs, thereby limiting the ability of an individual to neutralize multiple toxins [11]. 
Understanding the clinical correlates of SAg expression are further complicated because of the 
varied prevalence of individual SAg genes among different bacterial isolates, especially of S. 
aureus [12, 13]. Most of the SAgs, including staphylococcal enterotoxin A (SEA), SEB, SEC, and 
toxic shock syndrome toxin-1 (TSST-1), are encoded on variable genetic elements [14-17]. Thus, 
some strains express one or more SAgs while other strains can express a different pattern of SAgs. 
Finally, there is additional complexity because there is variation in SAg protein expression levels, 
with some evidence that SAgs SEB, SEC and TSST-1 may be expressed at higher levels than the 
other SAgs, due to transcriptional regulation [18]. 
Despite this variability in prevalence and expression levels, it is clear that the potency of 
SAgs is a direct cause of disease or at the least exacerbates a host of diseases. These include 
toxic shock syndrome (TSS), pneumonia, purpura fulminans, severe atopic dermatitis, and 
endocarditis [19-25]. While TSS is the disease most often associated with SAgs, especially TSST-
1, the frequency of staphylococcal or streptococcal infections in specific tissues (e.g. lung, skin, 
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soft tissue) results in SAg-mediated, hyper-inflammatory reactions at these sites [26, 27]. Specific 
inhibition of such severe tissue inflammation could be a useful adjunct to treatment of these 
diseases.   
Given the considerable structural information about SAgs and their interaction with Vβ 
domains, research in the Kranz laboratory has been directed toward engineering soluble versions 
of the Vβ domains against various SAgs for the purpose of developing potent neutralizing agents 
that could suppress the hyper-inflammatory properties of SAgs [28]. A similar receptor-based 
strategy has worked for neutralizing the effects of TNF-α with the soluble TNF-α 
receptor/immunoglobulin fusion Etanercept (trade name Enbrel) [29, 30]. Because of the low 
affinity of SAgs for their Vβ receptors, the reasoning has been that effective neutralization would 
require the generation of higher affinity variants of the Vβ, which would outcompete toxin 
engagement by cell-bound TCRs bearing any Vβ region since the same binding epitope on the 
SAg is used regardless of the Vβ region expressed by the T cell. To achieve this affinity 
maturation, directed evolution process and yeast display [31, 32] have been used, an approach 
that has yielded, to date, high-affinity Vβ proteins against the six SAgs: SEA (this work, Chapter 
2), SEB, SEC3, TSST-1, SpeA, and SpeC [28, 33-37]. Several of these have also been used 
successfully in animal models of S. aureus infections involving (TSS), pneumonia, skin disease, 
and endocarditis [20, 33, 35, 36, 38]. The engineered, high-affinity Vβ receptors also have dual 
use as specific and sensitive detecting agents, as described in Chapter 3. 
 
Structural features of the superantigens 
SAgs are structurally homologous, even though the primary sequences of the proteins are 
diverse [1, 5]. These proteins are globular and range between 20 and 30 kilodaltons [5]. 
Staphylococcal and streptococcal SAgs have been classified into five groups based on 
differences in their amino acid sequences [5]. Sequence alignments of specific members of these 
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groups (TSST-1 from Group I; SEB, SEC3 and SpeA from Group II; SEA from Group III and SpeC 
from Group IV), that have been the targets high-affinity Vβ regions engineered by yeast display 
(see below) are shown in Figure 1.1. These six SAgs have 10 to 65% sequence identity among 
each other. SEB, SEC3 and SpeA are 50 to 65% identical, and perhaps it is not surprising that all 
three stimulate T cells with the same Vβ, mouse Vβ8.2 [5]. Although SpeC belongs to a different 
group than SEB, SEC3 and SpeA, it exhibits significant sequence homology with these proteins 
in specific regions, despite having overall low sequence identity (21% identity with SEB and 
SEC3, and 24% identity with SpeA). Overall, TSST-1 is the most distant and contains the lowest 
level of sequence homology (and 7 to 20% identity) to these SAgs. 
Examination of the aligned sequences shows that there are several linear stretches of 
amino acids that are more similar among the six SAgs. However, examination of their co-crystal 
structures with the variable regions of beta chain (Vβ) of TCRs or with class II MHC ligands 
suggest that the regions interacting with these ligands are among the least homologous (Fig.1.1). 
These include residues at the N-terminus centered near position 20 which is part of the epitope 
for binding the Vβ region of the TCR [39-42]. Other Vβ binding regions are found between 
residues 90 to 95, and near the C-terminus of the protein sequences (positions 215-220), which 
also appear to lack the same degree of homology as flanking regions which are involved the 
structural framework for the SAgs. Thus, the residues in these regions, and also their atomic 
interactions with the cognate Vβ, most often differ and thereby account for the specificity of the 
interactions between SAg and the TCR. Nevertheless, SAgs that employ a zinc-dependent 
binding site for interaction with class II MHC ligands use conserved residues for coordinating zinc 
ion (Fig.1.1). 
SEA, SEB, SEC3 and SpeA also contain a conserved region (residues 45 to 55 in Fig.1.1) 
that serves as a binding site for class II MHC [43-47]. These same four SAgs, but not SpeC and 
TSST-1, possess a characteristic cystine loop of 9 to 19 residues [48, 49], which has been 
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implicated in emetic activity of SAgs. Toxins such as SpeC and TSST-1 that lack the cystine loop 
have been shown to exhibit reduced or no emetic activity [50]. 
Although many of the staphylococcal and streptococcal SAgs possess overall low 
sequence identity, their structures possess striking similarity. The canonical structure consists of 
a N-terminal, β-barrel containing domain and a C-terminal domain containing a β-grasp motif and 
an α-helix which spans the center of the structure, connecting the two domains [5] (Fig.1.2). In 
the past two decades, a number of crystal structures of SAg have been solved some of which are 
listed in Table 1.1. Co-crystal structures with the Vβ region of TCR or class II MHC, have provided 
the basis for understanding SAg interactions with receptors on T cells and antigen presenting 
cells. The different modes of interaction of each SAg with these receptors reveal the diversity in 
mechanisms of binding to Vβ and class II MHC, which is particularly intriguing considering they 
possess highly conserved three-dimensional folds.  
Four different modes of interaction of SAgs with class II MHC have been described: (1) 
SEB, SEC, SpeA bind to class II MHC alpha chain with a single, low affinity binding site that is 
located in the N-terminal domain of the protein. This binding is independent of the peptide located 
in the groove of the MHC-II molecule. (2) TSST-1 on the other hand uses a peptide-dependent 
binding mechanism to interact with low affinity to the class II MHC alpha chain through the TSST-
1 N-terminal binding domain. (3) SpeC binds to the beta chain of class II MHC with high affinity, 
in a zinc-dependent manner through the C-terminal domain of SpeC. (4) SEA contains both a low 
affinity binding site and a high affinity, zinc-dependent site which could possibly involve cross-
linking of MHC molecules [43-45, 47, 51, 52].   
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Process of engineering high-affinity T cell receptor Vβ domains against superantigens 
SEA, SEB, SEC3, TSST-1, SpeA, and SpeC 
Except for staphylococcal enterotoxin H (SEH), which has been shown to interact primarily 
with the variable region of the alpha chain (Vα) of the TCR [53, 54], SAgs are known to specifically 
interact with variable regions of TCR beta chain (Vβ). The hallmark feature of SAgs is that they 
stimulate T-cells that bear a specific subset of variable regions in their beta chains (Vβ) [55, 56]. 
Interestingly, despite their potent activity, SAgs are known to bind to their cognate Vβ receptors 
with low affinity (KD values in the micromolar range) (Table 1.2 and [57-59]). Several soluble, high-
affinity TCR Vβ mutants have been engineered for purposes of developing antagonists that can 
effectively neutralize their toxic effects in vivo, or for detecting them in food sources, or culture 
supernatants of potential pathogenic strains of Staphylococcus aureus and Streptococcus 
pyogenes [28, 33-37]. These Vβ mutants bind to one of six key staphylococcal and streptococcal 
SAgs (SEA, SEB, SEC3, TSST1, SpeA, and SpeC), at the same epitope as the wild type 
receptors but with much higher affinity, in the picomolar to nanomolar range. These represent 
1,000 to 3,000,000-fold increases in affinity, compared to wild-type (Table 1.2). Unlike antibodies, 
which could bind to any epitope of the SAg, engineering of the Vβ ensures that the neutralizing 
agent binds the identical SAg epitope as the wild-type receptor, thereby ensuring that direct 
competition and corresponding neutralization occurs. 
The process of engineering high-affinity T cell receptor Vβ domains against SAgs SEA, 
SEB, SEC3, TSST-1, SpeA, and SpeC is described below. All high-affinity Vβ mutants were 
engineered using yeast display technology (Fig.1.3) [31, 32] and directed evolution. The process 
involved use of a wild type Vβ from TCRs known to be stimulated by the SAg of interest. This Vβ 
gene was cloned into the yeast display vector (pCT302) in frame with the yeast mating protein, 
Aga2 to be displayed on the yeast surface. The Vβ gene was flanked by hemagglutinin (HA) and 
c-myc tags, which served as probes of the protein expression. Unlike many antibody variable 
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domains, wild type Vβ domains typically require that one or more key mutations be engineered 
into the protein in order to be expressed on the yeast cell surface [60, 61]. To accomplish this, 
the Vβ gene was subjected to error-prone PCR to introduce random mutations, and the library 
was selected by fluorescence-activated cell sorting (FACS) with a conformation-specific anti-Vβ 
antibody (these are typically available commercially against most of the human Vβ regions). Anti-
Vβ antibody is used, rather than fluorophore-labeled SAg at this stage, as the affinity of the SAgs 
with wild type Vβ are so low that detection by flow cytometry is not possible. The mutated Vβ 
region that allows it to be expressed on the surface of yeast is often called a “stabilized Vβ” as it 
has been shown that such mutations yield stabilized, soluble domains [62] (Fig.1.4). 
Stabilized Vβ region genes serve as templates for either additional random mutagenesis 
or for site-directed mutagenesis to generate libraries (Fig.1.4) with mutations in the putative SAg-
binding sites. Typically, selection of the sites for mutagenesis was guided by the crystal structure 
of Vβ:SAg complexes. If structural information was not available, such as with the engineering of 
Vβ against SEA (Chapter 2), [37], residues in CDR2 were chosen to generate the first generation 
site-directed mutagenesis libraries because of its central role in the interaction of other Vβ regions 
with SAgs, as observed in Vβ:SAg crystal structures [39-42]. To construct the site-directed 
mutagenesis libraries, amino acid positions were encoded by randomized codons (NNS) in 
primers, and cloned by PCR using overlapping primers. PCR products were transformed into 
yeast cells by homologous recombination, yielding library sizes of 106-108 transformants.  
Pre-selected degenerate libraries typically exhibit no detectable binding with SAg by flow 
cytometry due to their low affinity, or loss of binding, by the great majority of mutants. To select 
for the rare Vβ mutants that exhibit higher affinity binding, libraries were subjected to several 
rounds of selection with a decreasing concentration of biotinylated-SAg, followed by staining with 
fluorescently-labeled streptavidin, and fluorescence-activated cell sorting (FACS). In each round 
of selection, a small fraction of cells that exhibited the top 1% fluorescence upon selection with 
8 
 
SAg of interest, were collected and expanded for subsequent rounds of screening. When a distinct 
yeast population with positive SAg-staining emerged after 3~4 rounds of selection, yeast cells 
were plated and higher affinity clones were isolated, characterized and sequenced. In the 
engineering of Vβ22 against SEA, mutations isolated from the CDR2 library alone were capable 
of increasing the SEA affinity by 25,000-fold (Chapter 2), [37]. Even more strikingly, with the 
engineering of mouse Vβ8.2 against SEB, mutations from one CDR2 library accounted for a 
220,000-fold increase of Vβ affinity with SEB (from 144 µM wild-type affinity to 650 pM for G2-5) 
[33]. These results have further validated the essential role of CDR2 loop in Vβ:SAg interactions 
(see below). 
Following the initial selection, additional mutagenized libraries were often constructed in 
regions (CDR1, HV4 and FR3) that flank CDR2 in the tertiary structure, using one or a 
combination of the first generation lead mutants as templates. After further affinity- or off-rate-
based selections, mutants exhibited a more modest 10 to ~100 fold further increase in affinity. 
The specific region(s) where higher affinity mutations were successfully isolated for each pair of 
Vβ/SAg reflected, in part, the diverse binding modes of the SAgs with their cognate Vβs. 
Ultimately, mutations isolated from multiple libraries could be combined to generate the highest 
affinity mutants that yielded 1,000 to 3,000,000-fold increases in affinity with targeted SAgs 
compared to the wild type Vβ. 
 
Topology of Vβ:superantigen interactions 
Crystal structures of five out of six SAgs discussed in this review have been solved in 
complex with their cognate Vβ receptor ligand (Fig.1.5 B-F) [39-42]. In general, the Vβ receptor 
docks in the cleft between the two domains of the SAg and uses its hypervariable loops (CDRs), 
or specific framework (FR) regions for engagement (Fig.1.5). Co-crystal structures of different 
SAg with their cognate Vβ ligands indicate that Vβ domains interact with the SAgs with 
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considerable diversity in positioning and in interaction chemistries. However, the CDR2 loop of 
Vβ appears to be central to each SAg-TCR interaction [63, 64] (Fig.1.5). Other regions of the Vβ 
appear to play important, but supporting roles, in the binding energy and specificity for the SAg 
[34, 63, 65]. 
SEB, SEC3 and SpeA (Group II SAg) are more structurally similar and each has been co-
crystallized with murine Vβ8.2 (mVβ8.2) [39-41]. As indicated, these three SAgs possess 50-65% 
sequence identity and they engage with the mVβ8.2 region of the TCR using similar residues 
(Fig.1.1), thereby determining their specificity for mVβ8.2. Accordingly, SEB, SEC3 and SpeA 
interact with mVβ8.2 with similar topologies (Fig.1.5), and they engage in intermolecular contacts 
primarily with CDR2 (accounting for 50%, 63% and 33% of total contacts respectively), HV4 and 
to some extent framework (FR) regions. 
The mechanisms by which these three SAgs interact with mVβ8.2 are largely dependent 
on the common conformation of CDR2 and HV4, although SpeA forms a distinct contact via its 
E94 residue, by forming hydrogen bonds with N28 of CDR1 loop of mVβ8.2 [41]. Since SEB and 
SEC3 depend primarily on interactions with main chain atoms of Vβ-CDR2, their Vβ binding 
specificity is considerably reduced. However, SpeA:Vβ8.2 interaction specificity appears to be 
enhanced because the interface involves H-bonds between side chain atoms from both SpeA and 
the Vβ molecule. 
In contrast, SpeC interacts with human Vβ2.1 (hVβ2.1) with more extensive use of the Vβ 
region, engaging all of the hypervariable loops. The specificity of the SpeC:hVβ2.1 interaction is 
increased by numerous H-bonds and van der Waals interactions with both main chain and side 
chain atoms of hVβ2.1. Non-canonical amino acid insertions in CDR1 and CDR2, and the 
presence of an extended CDR3 loop (at least in some β-chains), also increase the specificity of 
hVβ2.1 for SpeC [41]. 
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Human Vβ2.1 is also the highly restricted target of TSST-1. Thus, both SpeC and TSST-
1 interact with hVβ2.1 and both engage residues in CDR2 to make contacts with Vβ. Although the 
two toxins engage a few common residues in CDR2, each also uses other distinct, non-
overlapping regions for binding and for achieving specificity. TSST-1 uniquely binds FR3 while 
SpeC engages with Vβ in a distinct mode by making extensive contacts involving residues from 
CDR1, HV4, FR2, FR3 and CDR3 in Vβ [41, 42]. The specificity of TSST-1 for hVβ2.1 has been 
attributed to the involvement of hVβ2.1 FR3 residues E61 and K62. It has been speculated that 
TSST-1 does not activate T-cells bearing other Vβ domains because 75% of all other human TCR 
Vβ regions possess a proline at position 61, resulting in reduced conformational flexibility; this 
reduced flexibility could prevent the specific conformation required for interaction with TSST-1. In 
addition, the absence of a residue at position 62 in 50% of human TCR Vβ domains also 
contributes to the high specificity of TSST-1 for hVβ2.1 [42]. Finally, the residues that TSST-1 
uses to interact with Vβ2.1 share little homology with residues that other SAgs (including SpeC) 
interact with their cognate Vβ ligand (Fig.1.1), which further enhances TSST-1 specificity towards 
hVβ2.1. The molecular basis of the extreme Vβ specificity of TSST-1 has recently been 
determined to be the combination of both the non-canonical conformation adopted by CDR2 
region of the Vβ along with residues Y56 and K62 on FR3 region [64].  
 
Structural basis of high-affinity and specificity of the Vβ:SAg interactions 
Although CDR2 regions have served as the predominant site for improving the affinities 
of Vβ domains for binding to their SAgs, it is clear that other regions can also serve to enhance 
affinity through structural changes in each Vβ:SAg interface. The involvement of regions other 
than CDR2, also can contribute to the high level of specificity in Vβ:SAg interactions exhibited by 
the high-affinity Vβ mutants. Several structures have been solved of SAgs in complex with 
engineered, high affinity Vβ domains, thereby providing an understanding of the interactions that 
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confer both higher affinity and specificity [42, 66, 67]. Not surprisingly, multiple factors, including 
increases in van der Waals interactions, hydrogen bonds, hydrophobic interactions, cooperativity, 
and conformational flexibility have all been shown to be involved. The generation and structural 
basis of high affinity for select Vβ domains is discussed below. 
In order to generate a high affinity Vβ mutant for binding SEC3, mVβ8.2 was displayed on 
the surface of yeast and mutations were introduced by error-prone PCR, followed by site directed 
mutagenesis to combine mutations. One resulting mutant, called L2CM (KD = 7 nM) (also called 
mL2.1/A52V, a first generation variant of L3, Table 1.2) exhibited ~450 fold increase in affinity 
compared to the wild type [28]. The structural basis of the SEC3:Vβ interaction has been studied 
extensively by alanine scan mutagenesis [68], and the high-affinity interaction with L2CM has 
been examined for binding energetics [69] and crystallization of various L2CM variants [66]. 
Although L2CM contained nine mutations, only four (A52V, S54N, K66E, Q72H) were 
energetically significant [69]. Structural analysis [66] indicated that the A52V mutation in CDR2, 
allowed an increase in hydrophobic contact area and also induced conformational changes in 
Q72 of the Vβ. The S54N mutation in CDR2 participated in affinity maturation by allowing 
recruitment of water molecules to SEC3:Vβ interface hence mediating contacts between N26Vβ  
and N24Vβ with D204, K205 and F206 in SEC3. Residue K66 appeared to be conformationally 
restrained in the SEC3:wtVβ8.2 structure, but it adopted a more extended conformation when 
mutated to glutamate. This also resulted in loss of van der Waals interactions with SEC3 and 
unfavorable change in enthalpy of binding but a highly favorable entropic change, resulting in a 
higher affinity complex [69]. Mutations Q72H and A52V were shown to be involved in inducing 
subtle conformational changes in hypervariable loops, thereby affecting how CDR1 residues, and 
CDR2 residue 52, interacted with SEC3. Although the A52V mutation had a dominant effect in 
affinity maturation by mediating restructuring events of the hypervariable loops, Q72H had a minor 
but significant contribution to affinity maturation [66]. Recently, L2CM was further engineered by 
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incorporating additional mutations in CDR1, HV4 and framework regions to obtain mutant L3 (KD 
= 3 nM) (Table 1.2 and [36]). 
mVβ8.2 was engineered for binding to SEB with a remarkable 3-million fold increase in 
affinity relative to wild-type mVβ8.2 (Table 1.2 and [33]). The engineered protein (G5-8) was 
crystallized in complex with SEB [67]. The structural details of this complex indicated that 
lengthening CDR1 loop by incorporation of a serine residue at CDR1 residue 27a, and 
incorporation of additional mutations N28Y and H29F, resulted in a distinct conformation of CDR1 
loop. These mutations resulted in an increase in intermolecular contacts with SEB. Y28 in G5-8 
was involved in pi stacking interaction with R110 in SEB and in H-bond interaction with N60. 
Additionally, two mutations (A52I and G53R) acquired in CDR2, resulted in replacement of 
residues with smaller side chains to relatively larger side chains which resulted in an increase in 
van der Waals contacts and H-bond formation with N31, N60 and N88 in SEB. Overall, it was 
concluded that an increase in the number of intermolecular contacts between G5-8 and SEB 
resulted in the significant increase in binding affinity [67]. 
mVβ8.2 was also engineered for high affinity (KD = 270 pM) for SpeA, using yeast display 
[35]. Key mutations which were responsible for affinity maturation were acquired in CDR2 (G53K, 
S54H), CDR1 (N30K) and in HV4 (Q72R). The resulting mutant, KKR showed a 22,000 fold affinity 
improvement compared to wt Vβ8.2 (KD= 6 µM) [41]. Although there is no crystal structure of 
SpeA with the high affinity Vβ, revertant mutants and energy minimized computer modeling of the 
mutated Vβ-SpeA complex allowed predictions of the basis of the affinity increase. The analysis 
revealed that the side chain of arginine acquired at position 53 in mutant KKR could be 
accommodated in a binding pocket in SpeA and promoted favorable interactions with side chain 
oxygen of Y90 and E88 of SpeA. Not only could this account for the affinity maturation, it could 
contribute to reduced cross-reactivity with SEC3, yet the ability of mutant KKR to not only retain 
cross-reactivity with SEB but to do so with high-affinity. 
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The mutant of hVβ2.1 called D10 was engineered for high affinity (KD = 180 pM) against 
TSST-1, using yeast display (Table 1.2 and [34]). D10 contained 14 mutations relative to 
stabilized wt Vβ2.1 (EP-8). Of these 14 mutations, four were found to be energetically significant: 
three mutations in CDR2 (at residues 51, 52a and 53) and one mutation in FR3 (at residue 61). 
Surprisingly, positive cooperativity was observed between the distant mutations in CDR2 and FR3 
[65]. Crystal structure analysis indicated that changes in intermolecular contacts, buried surface 
and/or shape complementarity were not the primary driving factor in affinity maturation of hVβ2.1 
to TSST-1. Instead, altered conformational flexibility of D10 was proposed to have resulted in 
affinity increase by linking CDR2 and FR3 at the Vβ:SAg interface [42]. Using a similar approach, 
the hVβ2.1 region gene has also been engineered for high-affinity binding to SpeC [Wang & 
Kranz, Unpublished]. 
In Chapter 2, the hVβ22 region was engineered for high affinity binding (KD = 4 nM) to 
SEA using yeast display [37]. The engineered mutant called FL contained ten mutations, of which 
five were located in CDR2. In the absence of a crystal structure of SEA with cognate Vβ, it was 
proposed that the structural basis of high affinity was probably due to improved electrostatic 
interactions (due to mutations N52E and E53D in CDR2), and pi stacking interactions involving 
N51Y in CDR2 with Y94 and Y205 in SEA’s putative TCR binding site. 
 
High-affinity Vβ domains as neutralizing agents 
The first study to validate the use of soluble, high-affinity Vβ domains in the neutralization 
of SAg activity was performed with the Vβ L2CM against the SAg SEC3. This work showed that 
soluble L2CM, but not soluble wild-type Vβ8, was able to completely inhibit SEC3-mediated T cell 
cytolysis at nanomolar concentrations [28]. This same high-affinity Vβ was fused to a class II MHC 
molecule in an attempt to increase the avidity of the interaction with SEC3 [70]. Although the 
14 
 
fusion was shown to inhibit SEC3 activity in vitro, this study did not show whether the fusion had 
greater activity than the high-affinity Vβ alone.   
Subsequent studies showed that the high-affinity Vβ against SEB, G5-8, but not the wild-
type Vβ8.2, was able to inhibit both in vitro and in vivo activities of SEB [33]. In this study, the in 
vitro activity was shown to be progressively improved in comparing different generations of 
mutants, with KD values from 100 µM to 50 pM.  For example, the 50 pM G5-8 protein was more 
effective at inhibition (i.e. had a lower IC50) than the 650 pM G2-5 protein. Furthermore, the G5-8 
protein was administered to rabbits intravenously at the same time or after SEB administration, in 
an LPS-enhancement model of lethality. The protein was able to prevent death even at 
concentrations close to stoichiometric with the SEB.  In the same study, G5-8 administered daily 
to rabbits implanted with pumps containing SEB was able to prevent temperature increases and 
lethality due to the SAg. In a rabbit model of skin disease, G5-8 was able to inhibit the 
hypersensitivity reactions caused by SEB [38]. 
An in-frame fusion of the high-affinity G5-8 against SEB and the high-affinity D10 against 
TSST-1 (yielding a single 30kDa protein, expressed in E. coli) was able to completely inhibit the 
in vitro activity of both SEB and TSST-1 [71], raising the possibility that multiple SAgs might be 
neutralized with a single therapeutic. An alternative approach is to identify a high-affinity Vβ 
domain that cross-reacts with multiple SAgs. While this has not been possible for structurally 
distinct SAgs (e.g. SEB and TSST-1), it has been shown that Vβ domains against SEB (e.g. G5-
8) cross-reacted with high-affinity against SpeA, and that Vβ domains were capable of inhibiting 
both SEB and SpeA in the LPS enhancement models [35]. More recent findings showed that it is 
possible to engineer a cross-reactive neutralizing Vβ (L3) against both SEC3 and SEB [36]. 
The greatest clinical potential of soluble, high-affinity Vβ domains, aside from possible 
applications in biodefense, would be in serious diseases caused by S. aureus. The first study to 
show that high-affinity Vβ proteins were effective in diseases caused by S. aureus (i.e. rather than 
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the purified toxins), involved a rabbit model of pneumonia [20]. Rabbits receiving an intrabronchial 
inoculation (2 x 109 cells) of S. aureus USA400 strain CA-MRSA c99–529 (SEB+) were protected 
from death when treated with 100 µg of G5-8, administered intravenously on a daily basis. 
Subsequent studies have shown that the high-affinity Vβ L3 against SEC3 also protected rabbits 
exposed to an SEC-positive strain of MRSA (USA400 MW2) in the pneumonia model [36]. 
Interestingly, the same L3 protein was capable of significantly reducing the bacterial burden of 
the MRSA (USA400 MW2) strain in an infective endocarditis model [36]. These pre-clinical studies 
suggest that these small Vβ proteins could be used intravenously, with antibiotics, to manage 
staphylococcal diseases that involve SAgs. The diversity of SAgs among different strains of S. 
aureus will likely require that diagnostics be developed for detection of the specific SAgs in 
patients, or that a multi-targeted therapeutic that can neutralize many of the SAgs be developed.   
 
High-affinity Vβ domains as detecting agents 
In Chapter 3, my efforts were directed toward using high-affinity Vβ domains for detecting 
SAgs. Capture ELISAs as well as flow-cytometry based methods were developed for detection of 
each SAg. Multiplex assays using the flow-cytometry platform were also developed to detect 
several SAgs in the same sample. This approach allowed specific detection and also quantitative 
determination of staphylococcal SAgs SEA, SEB and TSST-1 in supernatants derived from 
cultures of 18 strains of Staphylococcus aureus (Chapter 3).  
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FIGURES 
 
Fig. 1.1. Multiple sequence alignment of various Superantigen sequences  
The sequence of each superantigen (SAg) was obtained from the PDB file corresponding to its 
crystal structure. Multiple sequence alignment (CLUSTAL W (1.81)) was performed using “Biology 
WorkBench” online tool. Positions with homologous amino acids in three or more SAg sequences 
are highlighted in yellow or green. Residues in red are involved in forming the characteristic 
disulfide loop in certain SAg. Residues underlined in red and in blue are involved in binding to Vβ 
and class II MHC, respectively. Residues in bold are involved in binding zinc. 
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Fig. 1.2. Two-domain architecture of Superantigens 
The canonical structure of SAg consists of two domains. The N-terminal domain (red) consists of 
a β barrel motif and C-terminal domain (blue) consists of a β-grasp motif and an α-helix which 
spans the center of the structure.   
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Fig. 1.3. Schematic of yeast display system for engineering high-affinity Vβ domains 
against Superantigens 
The Vβ libraries with various mutations are fused to the C terminus of the yeast mating protein 
Aga-2 to be displayed on the yeast cell surface. HA and c-myc tags are included in the fusion 
gene to probe and quantify the Vβ protein expression level. Fluorescent ligands include either a 
monoclonal antibody to the Vβ region or the SAg. 
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Fig. 1.4. General flow chart for the cloning, display and engineering of high-affinity Vβ 
domains by yeast display  
A Vβ clone that is specific for the SAg of interest is cloned into the yeast display vector, pCT302 
(Figure 3) and used to generate libraries of mutants. The libraries are selected with fluorescently-
labeled ligands, (e.g. conformation-specific anti-Vβ antibodies or the SAg of interest). Multiple 
rounds of selections are conducted to enrich the Vβ mutants with desired properties, which serve 
as templates for subsequent library design and screening to achieve desirable stability or affinity 
of Vβ with SAg. 
 
20 
 
 
Fig. 1.5. Co-crystal structures of six superantigens with cognate Vβ domain of the T cell 
receptor 
Except for SEA, the co-crystal structures of SAg (blue) with their cognate Vβ ligand (gray) are 
available in PDB (Table 1). In Panel A, the SEA crystal structure was manually docked with mouse 
Vβ16 crystal structure (PDB: 4ELK), that is 66% identical to human Vβ22 protein sequence. 
Residues of SAg interacting with Vβ are indicated in teal. Various regions of Vβ are colored as 
follows: CDR1 (green); CDR2 (Red); CDR3 (orange); HV4 (purple); FR2 (olive) and FR3 (yellow). 
Interacting residues of Vβ and SAg are displayed in stick configurations. 
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TABLES 
Table 1.1. Crystal structures of staphylococcal and streptococcal superantigens and their 
complexes with Vβ domains  
Organism SAg 
Crystal Structure 
(PDB code, ligand) 
Year Reference 
S. aureus 
SEA 
1ESF (co-crystallized with Cd2+) 1995 [72] 
S. aureus 1SXT (co-crystallized with Zn2+) 1996 [73] 
S. aureus 
SEB 
3SEB 1998 [74] 
S. aureus 1SBB (co-crystallized with mVβ8.2) 1998 [39] 
S. aureus 
3R8B(co-crystallized with affinity 
matured mVβ8.2 mutant G5-8) 
2011 [67] 
S. aureus 
SEC3 
1CK1 (co-crystallized with Zn2+) 2002 [75] 
S. aureus 1JCK (co-crystallized with mVβ8.2) 1996 [40] 
S. aureus 
2AQ3 (co-crystallized with affinity 
matured mVβ8.2 mutant L2CM) 
2005 [66] 
S. aureus 
TSST-1 
2QIL 1996 [76] 
S. aureus 
2IJ0 (co-crystallized with affinity matured 
hVβ2.1 mutant D10) 
2007 [42] 
S. aureus 
3MFG (co-crystallized with hVβ2.1 
stabilized wild-type EP-8) 
2011 [67] 
S. pyogenes 
SpeA 
1FNU (co-crystallized with Cd2+) 
1FNV (co-crystallized with Cd2+) 
1FNW (co-crystallized with Cd2+) 
2000 
[77] 
 
S. pyogenes 
1L0X(co-crystallized with mVβ8.2) 
1L0Y(co-crystallized with mVβ8.2 and 
Zn2+) 
2002 [41] 
S. pyogenes 
SpeC 
1AN8 1997 [78] 
S. pyogenes 1KTK (co-crystallized with hVβ2.1) 2002 [41] 
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Table 1.2. High-affinity Vβ domains that bind to various superantigens 
Organism SAg 
Wild-type 
 Vβ 
High-affinity Vβ Improvement 
in affinity 
(fold) 
References 
Name 
Affinity 
(µM) 
Name 
Affinity 
(pM) 
S. aureus SEA 
Human 
Vβ22 
100 FL 4000 25,000 
[37]  
(this work, 
Chapter 2) 
S. aureus SEB 
Mouse 
Vβ8.2 
144 G5-8 50 2,880,000 [33, 57] 
S. aureus SEC3 
Mouse 
Vβ8.2 
3 L3 3000 1,000 [36, 57] 
S. aureus TSST-1 
Human 
Vβ2.1 
2.3 D10 180 13,000 [34] 
S. pyogenes SpeA 
Mouse 
Vβ8.2 
6 KKR 270 22,000 [35, 57] 
S. pyogenes SpeC 
Human 
Vβ2.1 
20 HG_FI 500 40,000 
[41], Wang 
& Kranz, 
Unpublished  
 
  
23 
 
 
CHAPTER TWO 
ENGINEERING  A Vβ DOMAIN OF THE T CELL RECEPTOR FOR BINDING WITH HIGH 
AFFINITY TO STAPHYLOCOCCAL ENTEROTOXIN A (SEA)2 
 
Introduction 
Staphylococcus aureus is a ubiquitous microorganism that causes a wide range of 
conditions including food poisoning, skin rashes, pneumonia, endocarditis, and toxic shock 
syndrome. CDC estimated that for foodborne illnesses in the United States in 2011, S. aureus 
was among the top five pathogens. Other reports have suggested that S. aureus mediates 
approximately 240,000 food-borne illnesses per year in the United States [79]. It is known that S. 
aureus secretes a collection of enterotoxins that are heat resistant, 20-30 kDa proteins [3, 5, 80], 
which upon ingestion with food cause symptoms that include abdominal cramps, nausea, emesis 
and diarrhea.  
More than twenty staphylococcal enterotoxins (SEs) and SE-like proteins have been 
described, of which approximately half possess emetic properties [5, 81]. These enterotoxins, 
along with other toxins from Staphylococcus aureus and Streptococcus pyogenes, have been 
classified into five distinct homology groups. SEA, SED, and SEE are in Group III. SEA and SEE 
are 83% identical in sequence, while SEA and SED are 48% identical in sequence (SED and SEE 
are 50% identical in sequence). The structures of enterotoxins among the different groups have 
been shown to be remarkably similar, despite low sequence identity among many of the members. 
The canonical structure consists of an N-terminal, beta barrel containing domain and a C-terminal 
                                               
2 Sections of this chapter were published in Protein Engineering, Design and Selection (PEDS) journal as a research 
article: Sharma P., Postel S., Sundberg E.J., Kranz D.M. (2013) “Characterization of the Staphylococcal enterotoxin A: 
Vβ receptor interaction using human receptor fragments engineered for high affinity”, Protein Engineering Design and 
Selection,  26(12):781-9 
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domain that consists of a beta-grasp motif and an alpha helix which spans the center of the 
structure [39, 40, 43, 73, 82].  
Characterization of various food poisoning outbreaks throughout the world has indicated 
that the presence of SEA in food, either alone or with other enterotoxins such as SED, SEE and 
SEH, was most often associated with the illness [83-88]. It has been estimated that the dose of 
SEA that is capable of causing the disease was a few hundred nanograms per individual [84, 89]. 
Other than its role in inducing gastrointestinal problems, SEA is also known to act as a 
superantigen, inducing hyper-inflammatory reactions in conditions such as endocarditis and toxic 
shock [90, 91]. As discussed in the introductory chapter, superantigens mediate hyper-
inflammatory reactions because of their ability to stimulate a very large fraction of the body’s T 
cells, as compared to conventional peptide-major histocompatibility complex (MHC) antigens, 
resulting in massive release of inflammatory cytokines, including tumor necrosis factor-α (TNF-
α), interferon-γ (IFN-γ), and interleukin (IL-2), into the circulation or tissues [9, 80]. The 
mechanisms of these hyper-inflammatory reactions involve the binding of the superantigen to the 
Vβ region of the T cell receptor [39, 40, 42, 92] and also to a class II MHC product on an antigen 
presenting cell. This trimolecular interaction leads to the stimulation of a large fraction (e.g. 20%) 
of T cells because of the limited number of Vβ genes in human T-cell repertoire. This process 
differs from recognition of conventional peptide-MHC antigens which interact with the 
hypervariable regions (complementarity determining regions, CDRs) of both TCR chains (αβ), 
and typically stimulates only a small fraction (e.g. <0.1%) of T cells [93]. More recently, the 
involvement of a co-stimulatory molecule (CD28) on T cells has been proposed to be involved in 
the hyper-immune response against superantigens [94]. It is thought that the superantigen also 
binds to CD28 that interacts with B7 molecule on antigen presenting cells, hence providing the 
second co-stimulatory signal which is required to activate the T cells. The involvement of CD28 
25 
 
is proposed to be involved in formation of a potentially more stable complex at the immunological 
synapse, hence playing a role in T-cell activation [94]. 
For most superantigens, it is known that they interact with their cognate Vβ receptors with 
low affinity (KD in micromolar range) [57-59]. Although SEA was the first S. aureus enterotoxin 
discovered from a strain isolated from a food poisoning outbreak [95, 96], the details of its 
interaction with its cognate Vβ receptor are largely unknown. As far as its interaction with class II 
MHC is concerned, investigators have established that SEA contains two separate binding sites 
for class II MHC molecule: a low-affinity binding site, and a high-affinity, zinc-dependent site, 
which possibly results in cross-linking of MHC molecules, hence activating antigen presenting 
cells, in addition to T cells [43, 52, 97].   
Several recent studies involving yeast surface display coupled with mutagenesis and 
superantigen-binding selections have been conducted to isolate mutants of various Vβ proteins 
(mouse Vβ8, human Vβ2), that were stabilized for expression as soluble proteins, and that had 
enhanced affinity for superantigens, SEB, SEC, or TSST-1 [28, 33-36]. These engineered Vβ 
proteins have enabled the structural characterization of their interactions with the cognate toxin 
[42], as well as studies on the molecular basis of affinity improvement [67]. Following an 
analogous process, I engineered soluble forms of both the wild-type receptor and a high-affinity 
Vβ receptor of SEA, for purposes of understanding its molecular interactions with SEA. Because 
of its high affinity, the engineered Vβ receptor developed in this study was also useful in 
developing specific, sensitive assays for detection of SEA.  
Based on earlier studies showing that human T cells expressing the Vβ22 region were 
selectively expanded when stimulated by SEA [98], I chose human Vβ22 as a target for 
engineering for improving its affinity towards SEA. As with other Vβ22 domains, the wild-type 
Vβ22 was not expressed well on the surface of yeast. However, I selected for increased surface 
expression among random Vβ22 mutants, and identified several framework mutations in Vβ22 
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gene that enabled surface expression, and soluble expression of the mutant proteins. Like other 
superantigen:Vβ interactions, the Vβ22:SEA interaction had low affinity (KD = 100 µM). Affinity 
engineering by selection from a collection of directed Vβ22 libraries revealed the importance of 
the CDR2 region of Vβ22 in its interaction with SEA. Mutations in CDR2 alone were capable of 
increasing the SEA affinity by 25,000-fold. The highest affinity mutant bound to SEA with a KD 
value of 4 nM, and exhibited a high level of specificity for SEA. The results provided insights into 
the mode of interaction of Vβ22 with SEA, and the affinity-engineered Vβ22 was also employed 
for development of sensitive assays for detection of SEA (2.5 ng/ml by capture ELISA, 0.4 ng/ml 
by bead-based, flow cytometry assay) and as a component of multiplex detection system for 
staphylococcal and streptococcal toxins, as discussed in chapter 3. 
 
Materials and Methods 
Cloning and expression of human Vβ22 on yeast cell surface  
The gene encoding human Vβ22 (referred to as hVβ22, hereafter) (Accession number: 
M64351), synthesized and codon optimized for expression in both E. coli and Saccharomyces 
cerevisiae (Genscript USA Inc.), was subcloned as an Aga-2 fusion (under the control of GAL1 
promoter) into yeast display vector pCT302 that contains an N-terminal hemagluttinin (HA) and a 
C-terminal myc (c-myc) tag (Fig. 2.1 A). HA and c-myc tags served as internal controls for protein 
expression. AGA-2 is a yeast mating agglutinin protein and allows the expression of the protein 
of interest on the yeast cell surface as a fusion protein [32].  
S. cerivisiae EBY100 strain was transformed with hVβ22-pCT302 construct, followed by 
plating on selective media (SD-CAA (Trp-) agar plates). Single colony was cultured in SD-CAA 
(Trp-) media at 30°C for 48 hours, followed by induction in galactose containing, SG-CAA (Trp-) 
media at 20°C for 48 hours. For analyzing expression of HA, Vβ22 and c-myc on the surface, 
induced yeast cells were incubated with anti-HA antibody (1:50 dilution) (mouse IgG1, clone 
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HA.11, Covance), anti-Vβ22 antibody (1:10 dilution) (mouse IgG1, clone: IMMU546, Beckman 
Coulter), or anti-c-myc antibody (1:100 dilution) (chicken IgY, Life Technologies), followed by 
washing and incubation with Alexa Fluor 488-conjugated secondary antibody (1:100 dilution) 
(goat anti-mouse or goat anti-chicken, Life Technologies). After washing, cells were analyzed by 
flow cytometry. 1X PBS (containing 0.5% BSA) was used for diluting all reagents and washing 
the cells. 
 Construction of random mutagenesis (error-prone) library and selection of stabilized Vβ22 
mutants  
Error-prone PCR was used to generate a library of random mutants of hVβ22 gene [99, 
100]. The hVβ22 gene was amplified from the pCT302 plasmid using the flanking, splice 4L and 
T7 promoter primers. PCR products with random mutations were then electroporated into the S. 
cerivisiae EBY100 strain, along with NheI and XhoI digested pCT302 vector. The library in yeast 
was generated by homologous recombination, followed by expansion in SD-CAA (Trp-) media at 
30°C for 48 hours to allow the growth of yeast cells that were transformed with pCT302 vector. 
Based on counting the number of colonies obtained after plating different dilutions of error-prone 
library on selective media (SD-CAA (Trp-) agar plates), approximate library size was calculated.  
The expanded error-prone library was cultured in galactose containing, SG-CAA (Trp-) 
media at 20°C for 48 hours to induce protein expression. After induction, the yeast library was 
incubated with 1:10 dilution of anti-Vβ22 antibody (mouse IgG1, clone: IMMU546, Beckman 
Coulter) for one hour on ice. Cells were then washed with 1X PBS (containing 0.5% BSA), 
followed by incubation with goat anti-mouse IgG F(ab’)2 conjugated with Alexa Fluor 488 or 647 
secondary antibody (Life Technologies) for one hour on ice. After washing, the yeast library was 
subjected to several rounds of selection using a FACS Aria cell sorter (BD Bioscience). After each 
sort, the most fluorescent cells from the library were collected and cultured in SD-CAA (Trp-) 
media, and then induced in SG-CAA (Trp-) media for next sorting procedure. After five sorts, 
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individual yeast clones were obtained by plating the sorted cells on selective media (SD-CAA 
(Trp-) agar plates) and their sequences were analyzed. 
Flow cytometric analysis of mutants isolated from error-prone library  
Individual yeast clones isolated from error-prone library, were cultured in SD-CAA (Trp-) 
media at 30°C for 48 hours, followed by induction in SG-CAA (Trp-) media at 20°C for 48 hours. 
Expression of HA, Vβ22 and c-myc was examined by incubating the cells with anti-HA antibody 
(1:50 dilution) (mouse IgG1, clone HA.11, Covance), anti-Vβ22 antibody (1:10 dilution) (mouse 
IgG1, clone: IMMU546, Beckman Coulter), or anti-c-myc antibody (1:100 dilution) (chicken IgY, 
Life Technologies), followed by washing and incubation with Alexa Fluor 488-conjugated 
secondary antibody (1:100 dilution) (goat anti-mouse or goat anti-chicken, Life Technologies). 
After washing, cells were analyzed by flow cytometry. 
For assessing binding of wt Vβ22 or Vβ22 mutants to SEA (Toxin Technology, Inc.), 
induced yeast cells were incubated with various concentrations of non-recombinant, biotinylated-
SEA, followed by washing and incubation with streptavidin-Alexa Fluor 488 conjugate (Life 
Technologies) at 1:200 dilution. After washing, yeast cells were analyzed by flow cytometry. 
Thermostability analysis of selected mutants isolated from error-prone library  
Selected mutants of Vβ22 from the error-prone library were subjected to thermostability 
analysis by incubating induced yeast cells at higher temperatures (up to 80ºC for 30 minutes) 
before incubation with anti-Vβ22 antibody. After incubating with anti-Vβ22 antibody (1:10 dilution) 
for an hour, the cells were washed and incubated with Alexa Fluor 488-conjugated secondary 
antibody (1:100 dilution) (Life Technologies). After washing, yeast cells were analyzed by flow 
cytometry. 
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Construction of directed mutagenesis (affinity) libraries and selection of high-affinity, SEA-binding 
Vβ22 mutants  
Thermostable Vβ22 mutants obtained from the error-prone library were used as templates 
for making directed mutagenesis libraries. Degenerate primers were used to introduce diversity 
in CDR2 region (residues 49 to 54) of Vβ22. Three overlapping, 4-codon libraries were generated, 
randomizing 4 residues at a time. PCR products were electroporated into S. cerivisiae EBY100 
strain, along with NheI, XhoI digested pCT302 vector for generation of directed mutagenesis 
libraries by homologous recombination. Libraries were mixed in equal proportion and subjected 
to several rounds of sorting for selecting Vβ22 mutant proteins that could bind to SEA with higher 
affinity. With each round of sorting, a lower concentration of SEA (biotinylated, non-recombinant) 
(Toxin Technology, Inc.) was used (1μM to 10nM), in order to obtain high-affinity mutants. Binding 
was assessed by staining with streptavidin-Alexa Fluor 488 or 647 conjugate (Invitrogen) at 1:200 
dilution. Individual yeast clones were isolated after sorting the library seven times, and analyzed 
by flow cytometry for protein expression on cell surface and binding to SEA. Distinct clones were 
identified by DNA sequencing. 
Off-rate analysis of various Vβ22 mutants  
Induced yeast cells expressing various mutants of Vβ22 were incubated with 10 nM 
biotinylated-SEA (non-recombinant) at 4°C. Cells were washed to remove unbound ligand, and 
then incubated with 100 nM recombinant SEA (unlabeled) at 37ºC for 24 hours. Aliquots of yeast 
cells were removed at regular intervals to monitor the dissociation of biotinylated SEA molecules. 
Each aliquot of cells was saved at 4°C until the end of time course, after which they were 
incubated with streptavidin-Alexa Fluor 647 conjugate (1:200 dilution) for 30 minutes. After 
washing, the cells were analyzed by flow cytometry. 
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Effect of site-directed mutations at residues 30 in CDR1, and 49-54 in CDR2 in Vβ22 mutants 
Site-directed mutations were generated at residues 30, 49, 50, 51, 52, 53 and 54 in 
different Vβ22 mutants isolated from CDR2 libraries, using Quikchange Lightning Kit (Stratagene) 
as described by the manufacturer. After transformation into S. cerivisiae EBY100 strain, protein 
expression on yeast cell surface and binding to SEA by each mutant, was analyzed by flow 
cytometry. 
Biotinylation of recombinant SEA  
Recombinant SEA (Toxin Technology, Inc.) was biotinylated at primary amines using EZ-
Link™ Sulfo-NHS-LC-Biotin (Pierce). After removing excess biotin, biotinylation of SEA was 
assessed by incubating with streptavidin (SAv) and analyzing change in mobility (“gel-shift”) on 
4-20% polyacrylamide gel. Biotinylated SEA was quantified by BCA Protein Assay kit (Thermo 
Fisher Scientific Inc). 
Experiments to determine unknown component in non-recombinant SEA preparation that bound 
to PS7-2 mutant with high affinity  
Soluble PS7-2 was immobilized on Dynabeads® M-270 Epoxy beads (Life Technologies) 
which possess surface epoxy groups, hence allowing direct covalent binding of proteins via 
primary amino or sulfhydryl groups. Immobilization of soluble PS7-2 on the surface of beads was 
performed at 4°C or 37°C. To assess the time required for immobilization, the reaction was 
allowed to proceed to different time points (4, 8, 12, 24 hours). After washing any unbound protein, 
the PS7-2 coated beads were incubated with 1 mg/ml biotinylated, non-recombinant SEA. After 
one hour, the beads were washed and then incubated with streptavidin-Alexa Fluor 647 conjugate 
(Life Technologies) at 1:200 dilution. After washing, the beads were analyzed by flow cytometry. 
For determining the unknown component in non-recombinant SEA preparation that bound 
to PS7-2 mutant with high affinity, PS7-2 was incubated with Dynabeads for four hours at 4°C. 
After washing any unbound protein, the beads were incubated with 1 mg/ml biotinylated, non-
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recombinant SEA. After one hour, PS7-2 coated beads were washed and shipped to Dr. Jeffrey 
A. DeGrasse at FDA for mass spectrometric analysis, who digested the proteins bound to the 
beads and analyzed the resultant peptides by LC-MS. 
Sorting directed mutagenesis (affinity) libraries with recombinant, biotinylated-SEA and selection 
of true, high-affinity, SEA-binding Vβ22 mutants  
Three directed mutagenesis libraries in CDR2 region (residues 49 to 54) of Vβ22 were 
mixed in equal proportion and subjected to several rounds of sorting for selecting Vβ22 mutant 
proteins that could bind to recombinant SEA with higher affinity. With each round of sorting, a 
lower concentration of SEA (biotinylated, recombinant) (Toxin Technology, Inc.) was used (1μM 
to 10nM), in order to obtain high-affinity mutants. Binding to biotinylated-SEA (recombinant) was 
assessed by staining with streptavidin-Alexa Fluor 647 conjugate (Invitrogen) at 1:200 dilution. 
Individual yeast clones were isolated after sorting the library six times, and analyzed by flow 
cytometry for protein expression on cell surface and binding to SEA. Distinct clones were 
identified by DNA sequencing. 
Expression and purification of soluble Vβ22 mutant proteins  
Specific Vβ22 mutants were subcloned into a pET28a expression vector (Novagen) for 
protein expression in E. coli BL21 (DE3) cells as inclusion bodies. Proteins were refolded (by slow 
dilution) from denatured inclusion bodies, followed by affinity purification with Ni agarose resin 
(Qiagen) and HPLC (Biocad Sprint) using a Superdex 200 (GE Healthcare) size exclusion column 
as described previously [33]. Secondary structure of refolded FL mutant was analyzed by circular 
dichroism experiments conducted in collaboration with Irisbel Guzman Sanchez (graduate 
student in Gruebele Lab, Department of Chemistry, University of Illinois). 
Binding of soluble Vβ22 mutants to SEA  
Binding of soluble Vβ22 mutant proteins to SEA was examined by ELISA and surface 
plasmon resonance (SPR). For ELISA, soluble Vβ22 mutant proteins (5 μg/ml) were coated on 
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the wells of an ELISA plate. Unbound proteins were washed away with 1X PBS + 0.1% Tween-
20, and any unoccupied sites on the wells were blocked with blocking buffer (1X PBS + 0.5% 
milk). This was followed by incubation with varying concentrations of recombinant, biotinylated-
SEA, followed by washing the wells and incubating with 1:2000 dilution of streptavidin-conjugated 
horse radish peroxidase (HRP) enzyme. After washing the wells twice, TMB substrate (KPL, Inc.) 
was added and the colorimetric reaction catalyzed by HRP was allowed to proceed for ~ 2 
minutes, after which it was stopped by addition of 1N H2SO4 to yield a yellow colored product 
whose absorbance was measured at 450 nm using a plate reader (Biorad).  
Affinity constants and kinetic parameters for Vβ22:SEA binding were determined by SPR 
using a Biacore T100 instrument (GE Healthcare) by Dr. Sandra Postel in Dr. Eric Sundberg’s 
laboratory, University of Maryland. 500 RU (Response units) of recombinant SEA was 
immobilized on a CM5 sensor chip. Various concentrations of soluble Vβ22 proteins were injected 
over the sensor surface and response was recorded. Global kinetic fits of the data were performed 
using the BiaEvaluation 4.1 software. 
Capture ELISA for detection of SEA  
To measure binding of recombinant-SEA (not biotinylated), an SEA detection assay was 
used in a “capture ELISA” format. For this assay, soluble Vβ22 mutant proteins (PS5-1 or FL) 
were coated on the wells of ELISA plates at 5μg/ml. Unbound proteins were washed away with 
1X PBS + 0.1% Tween-20, and any unoccupied sites on the wells were blocked with blocking 
buffer (1X PBS + 0.5% milk). Vβ22 mutant protein molecules immobilized on the wells were used 
to “capture” various concentrations of recombinant-SEA. After washing, 50 µl of 1:1000 dilution 
of rabbit anti-SEA (whole antiserum, Sigma-Aldrich) was added to the wells, followed by washing 
and incubation with 1:2000 dilution of goat-anti rabbit IgG(H+L) labelled with HRP (Sigma-
Aldrich). After washing the wells twice, TMB substrate (KPL, Inc.) was added and the colorimetric 
reaction catalyzed by HRP was allowed to proceed for ~ 2 minutes, after which it was stopped by 
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addition of 1N H2SO4 to yield a yellow colored product whose absorbance was measured at 450 
nm using a plate reader (Biorad). 
Cross-reactivity of engineered Vβ22 protein with other superantigens  
For cross-reactivity studies, induced yeast cells expressing PS7-1 F49M L30S (FL mutant) 
protein on the surface were incubated with a mixture of 100nM recombinant biotinylated-SEA and 
various concentrations of non-biotinylated SEA, SED and SEE (Toxin Technology, Inc.) for 1 hour 
on ice. The amount of biotinylated-SEA bound to FL protein, was detected using streptavidin-
Alexa Fluor 647 conjugate by flow cytometry.  
 
Results 
Cloning and expression of human Vβ22 on yeast cell surface  
The human Vβ22 gene was cloned in frame with the yeast cell wall protein Aga-2, with 
flanking HA an c-myc epitope tags, in the yeast display vector pCT302 (Fig. 2.1A). The yeast 
display construct was transformed into yeast cells, which were then cultured in D-CAA, followed 
by induction in SG-CAA media. Induced yeast cells were analyzed for surface expression of HA, 
Vβ22 and c-myc using anti-HA antibody, anti-Vβ22 antibody and anti-c-myc antibody respectively. 
Although yeast cells containing the wild-type Vβ22 (wt Vβ22) construct showed detectable levels 
of the HA and c-myc tags, an antibody to the Vβ22 region did not detect the fusion on the surface 
of yeast cells (Fig.2.1B). These results suggested that the Vβ22 protein was not folded properly, 
as has been observed with several other Vβ domains [34, 101, 102]. 
Expression of stable, human Vβ22 on the yeast cell surface 
 In order to determine if a stable Vβ22 protein could be isolated, the wt Vβ22 gene was 
subjected to random mutagenesis by error-prone PCR. PCR products along with NheI and XhoI 
digested pCT302 vector, were transformed into yeast to generate error-prone library by 
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homologous recombination. The resulting library size was 2 x 106 transformants with an average 
of approximately 1 mutation per gene.  
The expanded error-prone library was induced in galactose-containing media, following 
which it was subjected to several rounds of sorting (FACS) with a saturating concentration of anti-
Vβ22 antibody. After five sorts, a population of most fluorescent cells was collected (Fig. 2.2B), 
from which ten yeast clones were isolated and analyzed by flow cytometry and DNA sequencing 
(Fig.2.3A). Nine out of ten Vβ22 mutants (except PS5-6) were detected on yeast cell surface with 
anti-Vβ22 antibody. Sequence analysis indicated that the PS5-6 clone did not acquire any 
stabilizing mutations, which explained the lack of anti-Vβ22 staining. This clone also did not 
express HA and c-myc on the cell surface, which probably happened due to an upstream mutation 
leading to inefficient export of fusion protein to the cell surface. T13A mutation in framework region 
(FR1) was acquired by eight out of the nine mutants indicating its importance in stabilizing Vβ22. 
Overall, four different classes of mutants were obtained (Fig. 2.4, Table 2.1). PS5-7 clone only 
acquired one mutation (D63G). Upon transforming PS5-7 plasmid DNA into yeast, Vβ22 
expression was not observed indicating that the clone probably contained multiple plasmids, and 
D63G mutation had no role in stabilizing Vβ22. Hence, representative mutants from the remaining 
three classes (PS5-1, PS5-2 and PS5-4) were carried forward for further experimentation and 
analysis. Flow cytometry experiments indicated that yeast cells expressing these stabilized, 
hVβ22 mutants (PS5-1, PS5-2 and PS5-4) also expressed higher levels of HA and anti-c-myc 
(Fig. 2.3B) indicating a greater number of the fusions were expressed and exported to the cell 
surface when the Vβ22 domain was stabilized. 
To further compare the stability of these three stabilized Vβ22 mutants, each was 
subjected to an irreversible thermal denaturation assay in which yeast cells expressing PS5-1, 
PS5-2 or PS5-4 were incubated at various temperatures, followed by flow cytometry with the anti-
Vβ22 antibody (Fig.2.5) [103]. The 50% melting temperatures of the proteins ranged from 40°C 
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(PS5-1) to 60°C (PS5-2, PS5-4). The PS5-2 and PS5-4 Vβ22 mutants exhibited the highest level 
of stability (Fig. 2.5B).  
As mentioned earlier, PS5-1, PS5-2 and PS5-4 acquired identical framework mutation, 
T13A, suggesting that this mutation was important in stabilization of the Vβ22 domain on the yeast 
cell surface. Another framework mutation, T82A, was acquired by PS5-1 and PS5-2 mutants 
indicating this mutation might also have a role in stabilizing Vβ22 (Fig. 2.4, Table 2.1). Since PS5-
4 lacked T82A mutation, this suggested that Q11L (framework) and L30S (CDR1) mutations might 
have contributed to its stability, in addition to T13A mutation. Higher stability of PS5-2 and PS5-4 
appear to be due to Q11L (framework), L30S (CDR1) and/or L97Q (CDR3). Interestingly, 
mutations in the framework regions resulted in substitution of polar amino acids (Thr, Gln and 
Met) with hydrophobic amino acids (Ala, Leu and Val). In contrast, mutations in CDRs resulted in 
substitution of a hydrophobic amino acid (Leu) with polar amino acids (Ser and Gln). Protein 
modeling indicated that the mutations in framework regions were located on the face opposite the 
antigen binding face of the Vβ (CDRs) (Fig. 2.6). 
Since the affinity of SEA for binding to wt Vβ22 was unknown, micromolar concentrations 
of SEA were chosen for assessing binding to stabilized Vβ22 mutants based on the observation 
that most superantigens have affinities for their Vβ ligands in the micromolar range [57, 58, 104]. 
Despite being stable and folded on the surface of yeast, none of the mutants showed detectable 
binding to biotinylated SEA (non-recombinant) at concentrations as high as 2.5μM, by flow 
cytometry (Fig. 2.7) 
Selection of high-affinity, SEA-binding Vβ22 mutants 
In order to engineer Vβ22 mutants for binding with higher affinity to SEA, stabilized Vβ22 
mutants PS5-1, PS5-2 and PS5-4 were used as templates for constructing various directed 
mutagenesis libraries (affinity libraries). In the absence of a crystal structure of the SEA:Vβ 
complex, I elected to start by generating libraries in the CDR2, which is known to be central in the 
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binding of other superantigens to their cognate Vβ receptors [39, 42, 64, 92, 105]. The CDR2 
region in Vβ22 consists of six residues. Three overlapping libraries were generated, each in a 
contiguous stretch of four amino acids in the CDR2 region (Fig. 2.8A). The three libraries, 
consisting of ~2 x 107 independent clones each, were combined and subjected to consecutive 
rounds of sorting with decreasing concentrations of biotinylated-SEA (non-recombinant) (1μM to 
10nM). As expected, incubation of the pre-sorted CDR2 libraries with 1μM SEA did not yield 
detectable staining (Fig. 2.8B, left). However, after four consecutive rounds of sorting with 1μM 
SEA, a distinct population of cells that bound to SEA was obtained (Fig. 2.8B, middle). After 
seventh sort, Vβ22 mutants that bound to 10 nM biotinylated SEA were obtained, of which twelve 
clones were isolated (Fig. 2.8B, right). Upon sequencing, four different mutants, designated PS7-
1, PS7-2, PS7-4 and PS7-6, were identified with highly conserved features among them (Fig. 
2.9). All the mutants (PS7-1, PS7-2, PS7-4 and PS7-6) retained the conserved T13A and T82A 
stabilizing mutations. The PS7-1 mutant was derived from the 50-53 CDR2 library, whereas PS7-
2, PS7-4 and PS7-6 were all derived from the 49-52 CDR2 library (Fig. 2.8, 2.9). The latter three 
mutants also retained the L30S mutation in CDR1 mutation. 
These mutants were verified to have improved binding to 10 nM biotinylated-SEA (non-
recombinant), compared with the stabilized mutant, PS5-1 (Fig. 2.10A). Binding titrations with 
biotinylated-SEA (non-recombinant) indicated that the approximate dissociation constants of 
PS7-1 was 30 nM, while that of the remaining three mutants ranged from 60-80 nM (Fig. 2.10B). 
In addition to SEA titrations, the Vβ22 mutants were examined to determine dissociation rates 
and half-lives of the Vβ22:SEA complexes. Three of the four mutants   (PS7-2, PS7-4 and PS7-
6) were able to bind SEA (non-recombinant) with long half-lives (e.g. ~40-50% of the SEA 
remained bound after 24 hours at 37°C) (Fig. 2.11). Both binding experiments and off-rate 
experiments indicated that the mutants derived from the 49-52 CDR2 library (PS7-2, PS7-4 and 
PS7-6) bound to SEA (non-recombinant) better than the mutant derived from the 50-53 library 
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(PS7-1). However it is important to note that in the dissociation experiment, recombinant SEA 
was used as a competing agent against bound, non-recombinant biotinylated SEA. In future 
experiments, it was realized that the non-recombinant SEA preparation from Toxin Technology 
Inc. was contaminated with an unidentified substance (along with SEB), to which mutants PS7-2, 
PS7-4 and PS7-6 were binding with high affinity (see below).  
Role of specific amino acids at positions 30, 49 and 52 in Vβ22 mutants isolated from CDR2 
library 
Conservation in the mutations (F49M, Y50S/A, N51Y, N52E/G and E53D) in the mutants 
isolated from CDR2 library suggested that they were important in high-affinity binding to SEA. In 
order to study the role of several of these mutations in binding, further mutagenesis studies were 
conducted.  
Since the PS7-1 mutant lacked the F49M mutation that was present in PS7-2, PS7-4 and 
PS7-6, I reasoned that its incorporation into PS7-1 might increase its SEA-binding affinity. 
Similarly, PS7-2, PS7-4 and PS7-6 contained L30S mutation that was absent in PS7-1. In order 
to study the effect of F49M and L30S mutations, I introduced these mutations in PS7-1. The 
mutants generated (PS7-1 F49M and PS7-1 L30S) were transformed into yeast cells and 
analyzed by flow cytometry for surface expression and binding to SEA (non-recombinant). The 
introduction of F49M mutation in PS7-1 resulted in moderate increase in binding to SEA, although 
the surface levels of PS7-1 and PS7-1-F49M were similar (Fig. 2.12, panels C and D).  
Introduction of L30S mutation in PS7-1 also resulted in moderate increase in binding to SEA, 
although this mutation resulted in increase in surface expression (Fig. 2.12, panels C and D). In 
order to assess if these mutations would act synergistically, F49M and L30S mutations were 
inserted into PS7-1 to generate PS7-1 F49M L30S mutant (or, FL mutant). Yeast cells 
transformed with FL mutant exhibited higher median fluorescence units (MFU) for expression on 
cell surface, and also for SEA binding, compared with PS7-1 (Fig. 2.12, panels C and D).  
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The PS7-1 mutant contained the N52E mutation, whereas the PS7-2, PS 7-4, PS 7-6 
mutants contained the N52G mutation. To examine the role of position 52 in the high-affinity state, 
I generated an E52G mutation in PS7-1, and the G52E mutation in PS7-2, PS 7-4, PS 7-6 
mutants. These four mutants were examined by flow cytometry with 10 nM SEA (non-
recombinant) and each of the reciprocal mutations showed a loss of SEA binding, to background 
levels (Fig. 2.13A). Thus, the glutamate at position 52 in PS7-1 and the glycine at the same 
position in PS7-2, PS7-4 and PS7-6 were important residues for SEA binding, but within the 
context of the surrounding mutations in these mutants. Staining with anti-Vβ22 antibody indicated 
that glycine was preferred residue at position 52 than glutamate, as far as surface expression was 
concerned (Fig. 2.13B). 
Difference in binding of PS7-2 mutant to non-recombinant SEA versus recombinant SEA 
preparation due to possible contamination of non-recombinant SEA with SEB 
During the course of experimentation, a selected mutant from CDR2 library was analyzed 
for binding to recombinant and non-recombinant SEA. For this purpose, recombinant SEA was 
biotinylated at primary amines using EZ-Link™ Sulfo-NHS-LC-Biotin (Pierce). Extent of 
biotinylation was analyzed by gel-shift assay (Fig. 2.14A). A change in the mobility of biotinylated, 
SEA (recombinant) was observed in the absence or presence of streptavidin. The streptavidin-
biotinylated SEA complexes were high molecular weight (perhaps larger than 250 kDa) and hence 
did not migrate from the wells, while the biotinylated SEA was seen as an expected ~25 kDa band 
on the polyacrylamide gel (Fig. 2.14A). 
 Flow cytometry experiments for binding of PS7-2 mutant to recombinant or non-
recombinant SEA indicated that the mutant bound poorly to recombinant SEA than to non-
recombinant SEA (Fig. 2.14B). This hinted that the PS7-2 mutant was possibly binding to an 
unknown component (possibly, another superantigen which co-purified with SEA) in the non-
recombinant SEA preparation from Toxin Technology, Inc. The company provided with the 
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information that the non-recombinant SEA was purified from the FRI722 strain of Staphylococcus 
aureus. Review of existing literature and also consultation with Dr. Patrick Schlievert (University 
of Iowa) confirmed that FRI722 is known to secrete SEB, SEK and SEQ, in addition to SEA [106]. 
In order to assess if the contaminant in the non-recombinant SEA preparation, was a 
known superantigen, different concentrations of SEB, SEC and TSST-1 were added to yeast cells 
expressing PS7-2, and binding was analyzed. Binding of PS7-2 to SEB, SEC or TSST-1 was not 
detected even when the superantigen was at a high concentration (1µM) (Fig. 2.14C). In a parallel 
experiment, high-affinity Vβ mutant proteins, G5-8, L3 and D10 (engineered against SEB, SEC 
and TSST-1 respectively) [33, 34, 36], were analyzed for binding with non-recombinant and 
recombinant SEA. While G5-8 did not show detectable binding to recombinant SEA, binding to 
non-recombinant SEA was seen. Similarly, L3 did not show detectable binding to recombinant 
SEA, but bound to non-recombinant SEA. Since L3 protein also has affinity towards SEB (KD = 
4nM) [36], these observations pointed toward possible contamination of non-recombinant SEA 
prep with SEB. Binding of D10 to recombinant or non-recombinant SEA was not detected, 
indicating the non-recombinant SEA preparation did not contain TSST-1 as a contaminant. 
In order to identify the unknown component in the SEA (non-recombinant) preparation that 
bound with high affinity to PS7-2 mutant, the protein was expressed in E.coli as inclusion bodies 
and refolded (Fig. 2.15A, B). Refolded PS7-2 protein was coated on Dynabeads for different time 
intervals, at either 37°C or 4°C. Coating of the PS7-2 protein on the surface of the beads was 
confirmed by assessing binding to non-recombinant SEA preparation, by flow cytometry. Results 
indicated that the coating reaction was complete within 4 hours, and more efficient at 4°C than at 
37°C. Such PS7-2 coated Dynabeads were washed and then incubated with 1 mg/ml biotinylated, 
non-recombinant SEA. Washed beads were shipped to Dr. Jeffrey A. DeGrasse at FDA, who 
performed tryptic-digestion on the proteins bound to the beads and analyzed the resultant 
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peptides by LC-MS. However, no other peptides other than those derived from SEA or Vβ22 
mutants were retrieved. 
Identification of true, high-affinity, SEA-binding Vβ22 mutants 
Since it was found that the PS7-2 mutant isolated from CDR2 libraries did not bind 
recombinant SEA well, yeast cells expressing CDR2 libraries were now subjected to consecutive 
rounds of sorting with decreasing concentrations of biotinylated-SEA (recombinant) (1μM to 
10nM). After six sorts, Vβ22 mutants that bound to 10 nM biotinylated SEA were obtained, of 
which several clones (prefixed as PS6 mutants) were isolated and analyzed for binding to 10 nM 
biotinylated SEA (recombinant) by flow cytometry (Fig. 2.16A). Upon sequencing, it was noted 
that the mutants that bound to 10 nM recombinant SEA had highly conserved features among 
them, and were derived from 50-53 CDR2 library, like the PS7-1 mutant that was isolated when 
the same libraries were sorted with non-recombinant SEA (Fig. 2.17). Because of these 
conserved mutations in PS7-1 and PS6 mutants, I hypothesized that the PS7-1 mutant (although 
isolated from CDR2 libraries by sorting with non-recombinant SEA), was a true recombinant-SEA 
binder. 
To assess how a selected mutant, PS6-A10 (isolated from CDR2 libraries sorted with 
recombinant SEA) would compare with PS7-1 (and its mutant, PS7-1 F49M L30S or FL mutant) 
and PS7-2, a binding titration with biotinylated-SEA (recombinant) was performed. The mutants 
derived from 50-53 CDR2 library (PS7-1, PS6-A10) and FL mutant bound to SEA (recombinant) 
at concentrations as low as 3 nM (Fig. 2.18 panels A and B). Comparatively, PS7-2 mutant 
(derived from 49-52 library) did not bind as well to 10 nM SEA (recombinant). Of all the mutants 
analyzed, FL mutant exhibited highest maximum median fluorescence units (MFU) for 
recombinant SEA binding. The higher MFU for SEA binding by FL mutant (PS7-1 F49M L30S) 
positively correlated with higher expression on yeast cell surface (Fig. 2.18C). 
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To understand the contribution of F49M and L30S mutations, yeast cells expressing PS7-
1, and single and double mutants of PS7-1 (PS7-1 F49M, PS7-1 L30S and FL) were subjected to 
binding titration with biotinylated-SEA (recombinant). All the Vβ22 mutants analyzed, could bind 
to SEA at concentrations as low as 0.3 nM (Fig. 2.19A). Although the maximum surface levels of 
PS7-1 and PS7-1 F49M were similar (Fig. 2.19C), and below that of L30S mutant, the F49M 
mutation, resulted in a modest increase in affinity, from 30 to 10 nM, for PS7-1 and PS7-1-F49M, 
respectively (Fig. 2.19B, left). As indicated, the introduction of the stabilizing mutation L30S into 
PS7-1 increased its surface expression significantly (Fig. 2.19C, left) and also had an effect on 
affinity (from 30 to 20 nM, for PS7-1 and PS7-1-L30S, respectively). Combining F49M and L30S 
mutations resulted in higher surface levels and higher affinity compared with PS7-1, with an 
estimated apparent KD of 15 nM (Fig. 2.19, panels B and C). Mutants PS7-2, PS7-4 and PS7-6 
were also compared with PS7-1 and its mutants. As shown, these mutants bound to ~3-10 nM 
recombinant SEA, but exhibited very low MFU although their surface expression was high (Fig. 
2.19, panels B and C, right). Following these experiments, FL mutant was identified as the best 
mutant which bound to recombinant SEA with high-affinity. In future experiments, FL mutant was 
expressed in soluble form for further analyzing its binding properties.  
Analysis of revertant mutants of Vβ22 mutant, “FL”  
For understanding the role of each amino acid in CDR2 of FL in contributing toward binding 
with high affinity to SEA (recombinant), single-site revertant mutants (to wt residues) of FL were 
generated. The mutants were transformed into yeast cells, and analyzed for SEA-binding and 
surface expression (anti-Vβ22 staining). The sequence of M49F mutant of FL was same as PS7-
1 L30S mutant that has already been discussed above. It was noted in mutants isolated from 
CDR2 libraries (with recombinant or non-recombinant SEA), that a non-aromatic residue (alanine) 
was often selected at position 50 in place of tyrosine (aromatic), and that an aromatic residue 
(tyrosine or phenylalanine) was often acquired at position 51 (Fig. 2.9, 2.17 and 2.20A). Hence, it 
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was my hypothesis that these mutations (Y50A and N51Y/F) were fulfilling a structural (space) 
requirement for binding with SEA. That is, to accommodate the conserved N51Y/F mutation at 
the SEA binding surface, the aromatic residue at position 50 was mutated to alanine that requires 
much less space. To test this hypothesis, I generated the FL A50Y mutant that possesses 
aromatic residues at position 50 as well as 51 (Fig. 2.20A). It was noted that the binding of this 
mutant to SEA was substantially inhibited (Fig. 2.20B). This suggested that the inhibition in 
binding possibly happened due to the molecular crowding caused by two adjacent aromatic 
residues at the SEA binding interface. The requirement of at least one aromatic residue at the 
SEA-binding interface was proved by the inhibition of binding by FL Y51 mutant (Fig. 2.20B). 
Similarly, the importance of acidic residues at position 52 and 53 was highlighted by decrease in 
SEA-binding by FL E52N, FL D53E and D53A mutants (Fig. 2.20A). Specifically, aspartate was 
essential at positon 53 for binding of FL mutant to SEA (Fig. 2.20A). Mutations in CDR2 did not 
greatly affect surface expression of the Vβ, except for the I54A mutation (Fig. 2.20C). It was 
interesting to note that mutations at this position were not selected when the CDR2 libraries were 
sorted for binding with SEA, probably because isoleucine at position 54 contributed to the stability 
of Vβ22 protein. Loss of stabilization of FL I54A mutant, may have resulted in its inability to bind 
SEA (Fig. 2.20B).  
Expression of soluble human Vβ22 mutant proteins and analysis of their binding to SEA 
Previous studies have indicated that mutants expressed at higher levels on the surface of 
yeast are also expressed at higher levels in secretion or refolding systems [62, 102, 107].  In order 
to study the SEA-binding properties of Vβ22, several of the Vβ mutants (PS5-1, PS7-1, PS7-2 
and FL) were expressed as inclusion bodies in E.coli, solubilized, refolded and subjected to gel 
filtration. The Vβ22 mutants had a tendency to multimerize, and hence only a small fraction was 
purified as monomers (Fig. 2.21A). The secondary structure of refolded, FL mutant was verified 
to consist of beta sheets by circular dichroism by the characteristic dip in molar ellipticity at ~ 217 
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nm (Fig. 2.21B). Circular dichroism experiments were conducted in collaboration with graduate 
student, Irisbel Guzman Sanchez (Gruebele Lab, Department of Chemistry, University of Illinois). 
Binding of refolded, soluble Vβ22 mutant proteins to SEA was examined by ELISA and 
surface plasmon resonance (SPR). The format of the ELISA titrations do not allow an accurate 
KD determination due to several washing steps, but a minimum KD value for proteins that have 
adequate dissociation kinetics can be estimated. As shown, the soluble, monomeric PS5-1 protein 
(equivalent to the wild-type SEA-binding domain, with the stabilizing mutations for expression) did 
not bind detectably (Fig. 2.22). In contrast, the soluble, monomeric mutants PS7-1, PS7-2 and FL 
bound to SEA with minimum estimated KD values of 55 ± 20, 135 ± 70 and 30 ± 5 nM, respectively 
(Fig. 2.22). The SEA-binding of PS5-1 and FL mutants were also analyzed by SPR. Based on 
SPR equilibrium measurements, the KD value of the PS5-1 protein was ~100 µM (Fig. 2.23A), 
similar to the low affinities of other superantigens for their Vβ regions [57, 58, 104]. The SPR-
based measurement of the KD value for the FL mutant was ~4 nM, a 25,000-fold improvement in 
affinity (Fig. 2.23B). 
Capture ELISA for detection of SEA 
The high affinity of the FL protein allows one to use it as a probe for detection of SEA in 
samples. Accordingly, I developed a capture ELISA assay for detection of SEA, in which 
immobilized high-affinity FL mutant was used to capture SEA. Polyclonal anti-SEA was then 
added to detect the bound SEA. Without any optimization, this assay detected SEA at a 
concentration of 1-10 nM (~100 ng/ml) (Fig. 2.24). In chapter 3, it was determined that the 
sensitivity of SEA detection by this method was ~2.5-10 ng/ml. 
Specificity of superantigen binding by engineered Vβ22 mutant FL 
Since the SEE and SED toxins are in the same group as SEA, and exhibit 83 and 48% 
sequence identity with SEA, respectively, I assessed cross-reactivity of the Vβ22 FL mutant with 
these related enterotoxins. For this purpose, I used a competition assay with yeast cells that 
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expressed the FL mutant. In this assay, biotinylated-SEA (recombinant) was incubated with 
various concentrations of unlabeled recombinant SEA, SED or SEE and the mixture was added 
to the yeast cells expressing FL protein on their surface. Bound biotinylated-SEA was detected 
with streptavidin-PE by flow cytometry. SEA was able to completely inhibit the binding at higher 
concentrations, and detectable inhibition was observed at concentrations as low as 5 nM. In 
contrast, binding (competition) of SED and SEE by the FL mutant was not detected even at the 
highest concentration, 500 nM (Fig.2.25). This result suggested that the FL mutant exhibited a 
high level of specificity for SEA. 
 
Discussion 
Among the various exotoxins secreted by S. aureus, enterotoxin A has been most often 
associated with food poisoning outbreaks involving S. aureus [83, 84, 86-88]. For this reason, 
there has been interest in developing rapid, sensitive assays for food safety testing. However, 
SEA is also known to act as a superantigen, inducing hyper-inflammatory reactions in conditions 
such as endocarditis and toxic shock [90, 91]. The goal of this study was to understand more 
about the molecular interactions involved in the superantigen activities, but the engineered, high-
affinity receptors developed in this effort also have dual use as specific, sensitive detecting 
agents.  
Like other superantigens, the mechanism by which SEA exerts hyper-inflammatory effects 
involves the simultaneous binding of the enterotoxin to class II MHC molecules on antigen 
presenting cells and to the Vβ domain of the T-cell receptor present on T cells. Co-crystallization 
of other S. aureus superantigens with Vβ receptors has revealed different topologies of binding 
[39, 40, 42, 92], but in each case the center of the interface has involved CDR2 [64]. Thus, in my 
efforts with the cognate receptor for SEA (Vβ22), I focused on creating initial libraries in the CDR2 
loop. If I had not isolated higher affinity variants within these libraries, I might have concluded that 
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the Vβ22:SEA interaction differs substantially from other superantigens (e.g. SEB, SEC, TSST-1, 
and SpeA, for which higher affinity variants were isolated from CDR2 libraries [28, 33-36]). 
However, I was able to isolate CDR2 mutants with up to a 25,000-fold improvement in affinity, 
supporting the notion that the CDR2 loop of Vβ22 also resides at the interface of its interaction 
with SEA. 
Unlike many VH domains, Vβ domains are typically unable to be expressed in soluble form, 
or on the surface of yeast [34, 60]. One of the key reasons for this is that Vβ residues that are 
normally buried at the interface with the constant region domain of the β-chain, are destabilized 
when exposed in the isolated Vβ domain. Similarly, the Vβ22 domain shown here was more stable 
on the surface of yeast when several key mutations were made in the region opposite the CDR 
(Fig. 2.6), where the β chain constant region would normally be located. Somewhat surprisingly, 
these stabilizing mutations in the framework of Vβ22 were substitutions to hydrophobic residues. 
One might have predicted for a region that is normally buried (e.g. at the Vβ:Cβ interface) the 
residues would prefer to be more hydrophilic when exposed. Interestingly though, some other Vβ 
regions do normally contain similar or identical same amino acid residues identified here in the 
mutated Vβ22 domains (Fig. 2.26). The yeast surface levels of the Vβ22 domain were also 
increased, irrespective of SEA binding, by two CDR loop mutations, L30S and L97Q. L30S was 
shown especially to have a significant effect on the total surface levels of Vβ22 protein. These 
changes may act by increasing the hydrophilicity of these exposed loops. It has been shown 
previously that CDR1 mutations also have a significant effect on stabilization of a Vα:Vβ single-
chain TCR [102] , and other Vα or Vβ domains have also been stabilized through CDR mutations 
[61] .   
The low affinity of SEA for the stabilized Vβ22 domain (KD value of 100 µM) is similar to 
that measured for other superantigen interactions such as SEB:Vβ8.2 [33, 57]. Despite this low 
affinity, superantigens are capable of potent activity in part because only a small fraction of the 
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surface TCRs on a T cell needs to be bound in order to trigger activity [108]. In addition, ternary 
interactions with Vβ and class II MHC can further stabilize the active complex [109]. Thus, SEA 
appears to follow the same principles of low-affinity interactions with the TCR as with other 
superantigens. 
The structural basis of how high-affinity Vβ22 mutants bind to SEA remains to be 
determined, but it was interesting that the two adjacent aromatic residues at positions 49 and 50 
in the wild type V region, were both mutated to other residues (Met and Ala, respectively), whereas 
the adjacent residue at 51 was mutated to an aromatic residue (Tyr). These substitutions may 
allow optimal positioning of the Tyr51 side chain for stacking interactions with SEA. Additional 
mutations at 52 and 53 in the FL mutant yielded two adjacent negative charged residues (N52E 
and E52D), which could play a role in enhanced electrostatic interactions with SEA. 
The putative TCR binding site on SEA has been proposed to include T21, N25, Y94, Y205, 
N207, and T208 [110-113]. These residues are closely located in the tertiary structure of SEA 
(Fig. 2.26A), and could form the binding site for Vβ. The aromatic residue (Y51) in the CDR2 
region of FL could potentially be involved in pi-stacking interactions with Y94 or Y205 from SEA. 
The only positions within or near these six SEA residues that differ between SEA and both SED 
and SEE are positions 206 and 207 (Fig. 2.27). Interestingly, both SED and SEE have negatively 
charged residues at position 207, which could pose an electrostatic repulsion with negative 
charges (residues 52 and 53) in the Vβ22 FL mutant’s binding site.  
Finally, the Vβ22 protein FL, with a 25,000-fold increase in affinity for SEA compared to 
the wild-type Vβ, was capable of being expressed, purified, and immobilized as a detection agent 
for SEA. This engineered, high-affinity Vβ22 mutant protein was used for development of a 
capture-ELISA (this chapter) and a flow-cytometry based platform (chapter 3) for specific 
detection of SEA. The engineered protein was also used as a component of a multiplex system 
for simultaneous detection of staphylococcal and streptococcal toxins (chapter 3), that was 
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successfully used for detection of SEA, SEB and TSST-1 in supernatants derived from cultures 
of S. aureus. The same approach can possibly be used to detect toxins in food. 
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FIGURES 
 
Fig. 2.1. Cloning and expression of human wt Vβ22 on yeast cell surface 
(A) Schematic of yeast display construct containing human Vβ22 gene. (B) Flow cytometric 
analysis of induced yeast cells transformed with hVβ22-yeast display construct shown in panel A. 
Yeast cells were incubated with anti-HA, anti-Vβ22 or anti-c-myc (black), followed by a secondary 
antibody conjugated to a fluorophore (Alexa-488). The fluorescence exhibited by the cells 
incubated with secondary antibody only is represented by the gray peak. 
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Fig. 2.2. Scatter plots indicating sub-populations of yeast cells at different stages of 
sorting the error-prone library 
Yeast cells transformed with error-prone library of human Vβ22 were sorted several times for 
binding with anti-Vβ22 antibody. Scatter plots indicating sub-populations of yeast cells in the 
sorted library after sort-1 (panel A) and sort-5 (panel B), are shown. The most fluorescent cells 
(shown in the polygon, maroon) after sort-5 were collected, from which distinct, stabilized Vβ22 
mutants were isolated in future experiments. 
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Fig. 2.3. Yeast surface display of human Vβ22 
(A) Ten yeast colonies obtained after plating sorted error-prone library were cultured and induced, 
followed by analysis of surface expression of HA, Vβ22 and c-myc by flow cytometry. Median 
fluorescence units obtained from histograms were used to generate bar graphs shown. 
Fluorescence in the presence of secondary antibody only is represented by gray bar. (B) 
Histograms representing flow cytometric analysis of induced yeast cells expressing either wt Vb22 
or mutant proteins (PS5-1, PS5-2 and PS5-4) isolated from error-prone library. The fluorescence 
exhibited by the cells incubated with secondary antibody only is represented by the gray peak. 
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Fig. 2.4. Amino acid sequences of distinct mutants obtained from error-prone library 
Four different mutants (PS5-1, PS5-2, PS5-4 and PS5-7) were isolated from Vβ22 error-prone 
library, after sorting it five times. Mutated residues are in bold (red); CDR regions are highlighted 
in gray. 
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Fig. 2.5. Thermostability analysis of stabilized Vβ22 mutants obtained from error-prone 
library 
(A) Induced yeast cells expressing stabilized Vβ22 mutant proteins (PS5-1, PS5-2 and PS5-4) 
were incubated at temperatures up to 80ºC for 30 minutes, before incubation with anti-Vβ22 
antibody. After washing, cells were incubated with secondary antibody conjugated to Alexa Fluor 
488. After washing, the cells were analyzed by flow cytometry. Fluorescence emitted by the cells 
in the presence of secondary antibody only is represented by the gray peak. (B) Median 
fluorescence units (MFU) obtained from histograms were used to generate melting curves shown. 
The point of 50% melting temperatures of individual mutants are indicated.  
53 
 
 
Fig. 2.6. Structural analysis of mutations in the framework region of human Vβ22 
The SEA crystal structure (blue) (PDB: 1ESF) was manually docked with mouse Vβ16 crystal 
structure (gray) (PDB: 4ELK), that is 66% identical to human Vβ22 protein sequence. mVβ16 
residues in the structure are underlined, while the corresponding residues in wt hVβ22 are 
indicated in parenthesis. The residues indicated in (red) correspond to the framework residues in 
Vβ22, which were mutated for protein stabilization. As indicated, the stabilizing mutations were 
located on the face opposite CDRs. CDR1 is shown in green, CDR2 in orange and CDR3 in pink. 
Putative TCR-binding residues of SEA are indicated in teal.   
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Fig. 2.7. Flow cytometry histograms for analyzing binding of wt Vβ22 and stabilized Vβ22 
mutants to various concentrations of SEA 
Induced yeast cells expressing either wt Vβ22 or stabilized mutant proteins (PS5-1, PS5-2 and 
PS5-4), were incubated with various concentrations of non-recombinant, biotinylated-SEA (nr-b-
SEA), followed by a streptavidin-Alexa Fluor 488 conjugate. The fluorescence exhibited by the 
cells incubated with streptavidin-Alexa-488 only is represented by the gray peak. 
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Fig. 2.8. Design and sorting of CDR2 libraries of Vβ22 
(A) Residue positions in Vβ22 sequence that were the target of three directed mutagenesis 
(CDR2) libraries are shown. Diversity was introduced at residue positions indicated with asterisk 
(*) using degenerate primers. (B) Yeast cells transformed with a mixture of three CDR2 libraries, 
were sorted several times with decreasing concentrations of non-recombinant, biotinylated-SEA 
(nr-b-SEA). Scatter plots representing different stages of sorting are shown. The cells indicated 
in the polygon (maroon) after sort-7 were collected, from which distinct Vβ22 mutants were 
isolated in future experiments. 
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Fig. 2.9. Amino acid sequences of distinct mutants isolated from CDR2 library 
Four different mutants (PS7-1, PS7-2, PS7-4 and PS7-6) were isolated from CDR2 libraries, after 
sorting multiple rounds with non-recombinant, biotinylated-SEA. Their sequences are compared 
with wt-Vβ22 and stabilized Vβ22 mutants (PS5-1, PS5-2, PS5-4) isolated from error-prone 
library. Two mutations (F49M and L30S) were introduced into PS7-1 to yield the mutant 
designated FL. Mutated residues are in bold (red); CDR regions are highlighted in gray. 
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Fig. 2.10. Binding analysis of distinct Vβ22 mutants isolated from CDR2 library 
(A) Histograms representing binding of Vβ22 mutants to SEA are shown. Induced yeast cells 
expressing four different Vβ22 mutants (PS7-1, PS7-2, PS7-4 and PS7-6) isolated from CDR2 
libraries, were incubated with 10 nM non-recombinant, biotinylated-SEA (nr-b-SEA), followed by 
a streptavidin conjugated with a fluorophore (Alexa Fluor 647). The fluorescence exhibited by 
yeast cells incubated with streptavidin-Alexa Fluor 647 conjugate only, is represented by the gray 
peak. (B) SEA-binding titration of Vβ22 mutants isolated from CDR2 libraries. Median 
fluorescence units (MFU) obtained from the histograms were used to generate binding curves 
shown. 
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Fig. 2.11. Off-rate analysis of various Vβ22 mutants  
Induced yeast cells expressing Vβ22 mutants (PS7-1, PS7-2, PS7-4 and PS7-6) isolated from 
CDR2 libraries or site-directed mutants of PS7-1, were incubated with biotinylated-SEA (nr-b-
SEA). After washing, dissociation of biotinylated-SEA was monitored by addition of a competing 
reagent (unlabeled SEA, recombinant, in this case). Aliquots of cells were removed at different 
time points, and stained with streptavidin conjugated with a fluorophore. Median fluorescence 
units (MFU) at each time point was recorded. % biotinylated SEA bound at each time point was 
calculated as 100*(MFU(time point) – MFU(negative control))/(MFU(positive control) – MFU(negative control)). In panel 
A, dissociation of bound, biotinylated SEA from 0 to ~20 hours is shown. In panel B, dissociation 
of bound, biotinylated SEA from 0 to 2.5 hours is shown. 
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Fig. 2.12. Effect of mutations at residues 30 and 49 in PS7-1 mutant 
Flow cytometry histograms indicating effect of introducing F49M and/or L30S mutations in PS7-1 
mutant are shown. Binding to 10 nM non-recombinant, biotinylated-SEA (nr-b-SEA) (panels A 
and C) and surface expression of Vβ22 protein (anti-Vβ22 staining in panels B and D) by yeast 
cells expressing various Vβ22 mutants were analyzed. The fluorescence exhibited by yeast cells 
incubated with streptavidin-Alexa Fluor 647 conjugate only (panels A and C) or secondary 
antibody only (Alexa Fluor 647-conjugated goat anti-mouse IgG in panels B and D) is represented 
by the gray peak. Stretches of Vβ22 sequence where mutations are located are shown in panel 
E. 
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Fig. 2.13. Importance of specific residues at position 52 isolated in Vβ22 mutants for 
binding to SEA 
To understand the role of specific amino acids at position 52, glycine was introduced in PS7-1 
while glutamate was introduced in PS7-2, PS7-4 and PS7-6. Binding to 10 nM non-recombinant, 
biotinylated-SEA (nr-b-SEA) (panel A) and surface expression of Vβ22 (panel B) by yeast cells 
expressing different Vβ22 mutants were analyzed. The fluorescence exhibited by cells incubated 
with streptavidin-Alexa Fluor 647 conjugate only (panel A) or secondary antibody only (Alexa 
Fluor 647-conjugated goat anti-mouse IgG in panel B), is represented by the gray peak. Stretches 
of Vβ22 sequence where mutations are located are shown in panel C.  
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Fig. 2.14. Difference in binding of PS7-2 mutant to non-recombinant SEA versus 
recombinant SEA preparation due to possible contamination of non-recombinant SEA with 
SEB 
(A) Gel-shift assay showing biotinylation of recombinant SEA. (B) Induced yeast cells expressing 
PS7-2 protein were incubated with 10 or 100 nM recombinant or non-recombinant, biotinylated 
SEA (r-b-SEA or nr-b-SEA), followed by incubation with streptavidin-Alexa Fluor 647 conjugate. 
Binding to SEA was assessed as an increase in fluorescence, compared to the fluorescence 
exhibited by the cells when no toxin was added (gray peak). (C) Induced yeast cells expressing 
PS7-2, G5-8, L3 or D10 protein on their surface, were incubated with 10 or 100 nM of the 
biotinylated toxins indicated, followed by incubation with a streptavidin-Alexa Fluor 647 conjugate. 
Binding to each toxin was assessed as an increase in fluorescence, compared to the fluorescence 
exhibited by the cells when no toxin was added (gray peak).   
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Fig. 2.15. Binding of soluble PS7-2 protein coated on Dynabeads to SEA 
(A) Test induction indicating expression of PS7-2 protein in transformed E.coli BL21 (DE3) cells 
upon induction with IPTG. Lysates of induced and uninduced cultures were loaded on 4-20% 
SDS-PAGE gels for assessing protein expression. (B) Purified PS7-2 protein loaded on 4-20% 
SDS-PAGE gel, after refolding inclusion bodies harvested from E.coli. (C) Soluble PS7-2 was 
coated on Dynabeads for 4, 8, 12, 24 hours at 4ºC or 37ºC. Coated beads were washed and 
incubated with non-recombinant, biotinylated-SEA (nr-b-SEA) followed by incubation with 
streptavidin-Alexa Fluor 647 conjugate. Binding to SEA was assessed as an increase in 
fluorescence, compared to the fluorescence emitted by the beads when no toxin was added (gray 
peak).  
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Fig. 2.16. Binding analysis of selected Vβ22 mutants isolated from CDR2 library after 
sorting with recombinant-biotinylated-SEA 
(A) Histogram representing binding of Vβ22 mutants to recombinant-SEA is shown. Induced yeast 
cells expressing three different Vβ22 mutants (PS6-A9, PS6-A10 and PS6-B2) isolated from 
CDR2 libraries, were incubated with 10 nM recombinant, biotinylated-SEA (r-b-SEA), followed by 
streptavidin-Alexa Fluor 647 conjugate. The fluorescence exhibited by yeast cells incubated with 
streptavidin-Alexa Fluor 647 conjugate only, is represented by the gray peak. (B) Histogram 
representing surface expression of Vβ22 on yeast cells expressing various Vβ22 mutants. 
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Fig. 2.17. Amino acid sequences of distinct mutants isolated from CDR2 library after 
sorting with recombinant-biotinylated-SEA 
Distinct Vβ22 mutants (prefixed with PS6 in the sequence analysis shown above) were isolated 
from CDR2 libraries, after sorting multiple rounds with recombinant, biotinylated-SEA. Their 
sequences are compared with wt-Vβ22, stabilized Vβ22 mutants (PS5-1, PS5-2, and PS5-4) 
isolated from error-prone library, and mutants isolated from CDR2 libraries (PS7-1, PS7-2) after 
sorting with non-recombinant, biotinylated SEA. Two mutations (F49M and L30S) were introduced 
into PS7-1 to yield the mutant designated FL. Mutated residues are in bold (red); CDR regions 
are highlighted in gray. 
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Fig. 2.18. Binding analysis of key Vβ22 mutants to recombinant SEA 
(A) Flow cytometry histograms for binding of PS7-1, PS7-2, PS6-A10 and PS7-1 F49M L30S (FL 
mutant) to various concentrations of recombinant, biotinylated-SEA (r-b-SEA). Fluorescence in 
the absence of SEA is represented by gray (filled) peak. Concentrations of SEA used are indicated 
in the histograms. (B) Median fluorescence units (MFU) obtained from histograms shown in panel 
A were used to generate binding curves shown. (C) Analysis of levels of surface expression of 
Vβ22 by various Vβ22 mutants is shown. (D) Stretches of Vβ22 sequence where mutations are 
located in the Vβ22 mutants being analyzed, are shown. 
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Fig. 2.19. Effect of mutations at residues 30 and 49 in PS7-1 mutant 
(A) Flow cytometry histograms for binding of PS7-1, PS7-1 F49M, PS7-1 L30S and PS7-1 F49M 
L30S (FL mutant) with various concentrations of recombinant, biotinylated-SEA (r-b-SEA). 
Fluorescence in the absence of SEA is represented by gray (filled) peak. Concentrations of SEA 
used are indicated in the histograms. (B) Median fluorescence units (MFU) obtained from 
histograms shown in panel A were used to generate binding curves shown. (C) Flow-cytometric 
analysis of levels of surface expression by various Vβ22 mutants is shown.  
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Fig. 2.20. Analysis of revertant mutants of high affinity Vβ22 mutant, “FL” 
Sequences of  wt Vβ22, mutants isolated from CDR2 libraries (PS7-1, PS6-A10), FL and its 
revertant mutants are shown in panel A. Effect of single-site revertant mutations on binding to 
SEA (panel B), and surface expression (panel C) was analyzed. The revertant mutants were 
transformed into yeast and analyzed for binding with different concentrations of recombinant-
biotinylated SEA (r-b-SEA) (panel B) or anti-Vβ22 (panel C). Median fluorescence units from flow 
cytometry histograms were used to generate the bar graphs shown. 
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Fig. 2.21.  Purification of refolded Vβ22 mutant proteins 
(A) Purification of monomeric fractions of refolded, high-affinity Vβ22 mutants by size-exclusion 
chromatography. Dashed line indicates the molecular weight standards. (B) Circular dichroism 
spectrum of refolded FL protein. 
  
69 
 
 
Fig. 2.22. ELISA-based titration for binding of soluble Vβ22 mutant proteins to 
recombinant, biotinylated SEA.  
Purified Vβ22 mutant proteins were coated on wells of an ELISA plate at 5μg/ml, followed by 
incubation with various concentrations of recombinant-biotinylated-SEA (r-b-SEA), followed by 
streptavidin-conjugated HRP. Bound SEA was detected by measuring absorbance of colorimetric 
product formed at 450nm, upon addition of TMB substrate. 
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Fig. 2.23. Binding analysis of selected Vβ22 mutants by surface plasmon resonance 
(A) SPR-based binding analysis for the interaction between immobilized recombinant, SEA and 
PS5-1 soluble protein. Non-linear regression analysis of maximal response versus concentration 
is depicted. Binding affinity constant for the interaction is indicated. (B) SPR sensorgram for the 
interaction between immobilized recombinant, SEA and affinity-matured Vβ22 mutant, FL. On-
rates (kon) and off-rates (koff) of the interaction were used to calculate the binding affinity constant 
for the interaction, as shown.  
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Fig. 2.24. Capture ELISA for detection of SEA 
Soluble Vβ22 mutant proteins (PS5-1 or FL) were coated on the wells of ELISA plates at 5μg/ml. 
These were used to capture various concentrations of recombinant SEA (r-SEA). Bound SEA was 
detected with anti-SEA antibody (whole antiserum, rabbit), followed by goat anti-rabbit IgG-HRP. 
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Fig. 2.25. High-affinity Vβ22 mutant FL does not cross-react with related toxins 
SED and SEE 
Induced yeast cells expressing FL protein on the surface were incubated in a mixture of 100 nM 
recombinant, biotinylated-SEA (r-b-SEA) and various concentrations of non-biotinylated SEA, 
SED and SEE. Bound, biotinylated SEA was detected using streptavidin-Alexa Fluor 647 
conjugate. Median florescence units (MFU) were recorded. % biotinylated-SEA bound was 
calculated as 100*(MFU(experiment) – MFU(negative control))/(MFU(positive control) – MFU(negative control)), and 
plotted against concentration of competing reagent to generate the curve shown. 
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Fig. 2.26. Structural analysis of specific residues in superantigen:Vβ interactions 
In panel A, the SEA crystal structure (blue) was manually docked with mouse Vβ16 crystal 
structure (gray) (PDB: 4ELK), that is 66% identical to human Vβ22 protein sequence. mVβ16 
residues in the structure are underlined, while the corresponding residues in wt hVβ22 are 
indicated in parenthesis. The residues indicated in (red) correspond to the framework residues in 
Vβ22, which were mutated for protein stabilization. Wild type residues at the same location in 
other Vβ proteins (gray) which have been crystallized in complex with other superantigens (blue), 
are indicated in red in panels B, C and D. Putative TCR-binding residues of SEA are indicated in 
teal in panel A; these are proposed to contact residues in CDR2 (orange) of Vβ22, in the current 
study. For all superantigens, CDR1 is shown in green, CDR2 in orange and CDR3 in pink. 
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Fig. 2.26 (cont.). Structural analysis of specific residues in superantigen:Vβ interactions 
In panel A, the SEA crystal structure (blue) was manually docked with mouse Vβ16 crystal 
structure (gray) (PDB: 4ELK), that is 66% identical to human Vβ22 protein sequence. mVβ16 
residues in the structure are underlined, while the corresponding residues in wt hVβ22 are 
indicated in parenthesis. The residues indicated in (red) correspond to the framework residues in 
Vβ22, which were mutated for protein stabilization. Wild type residues at the same location in 
other Vβ proteins (gray) which have been crystallized in complex with other superantigens (blue), 
are indicated in red in panels B, C and D. Putative TCR-binding residues of SEA are indicated in 
teal in panel A; these are proposed to contact residues in CDR2 (orange) of Vβ22, in the current 
study. For all superantigens, CDR1 is shown in green, CDR2 in orange and CDR3 in pink. 
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Fig. 2.27. Sequence alignment of SEA, SED and SEE 
Multiple sequence alignment between sequences of SEA, SED and SEE toxins. Putative TCR 
binding residues of SEA are boxed. 
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TABLES 
Table 2.1 . Classes of mutants obtained from Vβ22 error-prone library 
Nine Vβ22 mutants were isolated from the error-prone library after sorting it five times. Four 
classes of mutants were established based on the mutations they contained. Representative 
mutants from each class which were analyzed in this work are underlined. 
Class Mutants 
Location of mutations 
FR1 CDR1 FR3 CDR3 
1 
PS5-1 
PS5-3 
PS5-5 
PS5-8 
PS5-9 
PS5-10 
T13A 
M15V  T82A  
2 PS5-2 T13A  T82A L97Q 
3 PS5-4 Q11L 
T13A L30S   
4 PS5-7   D63G  
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CHAPTER THREE 
DEVELOPMENT OF A MULTIPLEX ASSAY FOR DETECTION OF STAPHYLOCOCCAL AND 
STREPTOCOCCAL TOXINS USING TWO-COLOR FLOW CYTOMETRY 3 
 
Introduction 
As discussed in previous chapters, Staphylococcus aureus and group A Streptococcus 
pyogenes secrete a family of pyrogenic toxins including staphylococcal enterotoxins A, B, C (SEA, 
SEB, SEC), toxic shock syndrome toxin-1 (TSST-1) and streptococcal pyrogenic exotoxins 
(SpeA, SpeC) which act as superantigens (SAg), hence resulting in overstimulation of the immune 
system. These T-cell mediated reactions are associated with hyperinflammation and in some 
cases, organ failure or death. Accordingly, these toxins have been incriminated in sepsis, toxic 
shock syndrome (TSS), infective endocarditis, and skin conditions like atopic dermatitis etc. [2, 5, 
114].  
Some of the staphylococcal toxins are also associated with food poisoning. Although SEA 
has often been linked to food poisoning outbreaks [83-88], staphylococcal enterotoxin B, C, D, E 
and H have also been shown to be present in some cases [86, 115-118]. In the United States, it 
has been estimated that Staphylococcus aureus mediates approximately 240,000 food-borne 
illnesses per year [79]. Even if the organisms can be destroyed through a sterilization program, 
staphylococcal enterotoxins are heat stable and potent at consumption levels as low as a few 
hundred nanograms [84, 89]. As 20 to 30% of humans carry S. aureus as a commensal in their 
skin, its dissemination into foods because of improper handling is a risk factor for food-borne 
illnesses, compounded by issues associated with improper storage which allows that can allow 
                                               
3 Sections of this chapter were submitted to PLOS ONE journal as a research article: Sharma P., Wang N., Chervin, 
A.S., Quinn C.L., Stone J.D., Kranz D.M. (2015) “A Multiplex Assay for Detection of Staphylococcal and Streptococcal 
Exotoxins”. 
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growth of bacteria and subsequent production of enterotoxins [119]. Like Staphylococcus aureus, 
Streptococcus pyogenes colonizes human beings and also produces superantigenic toxins 
including SpeA, SpeC, SMEZ and SSA have also been linked with conditions like sepsis, 
streptococcal TSS, scarlet fever and guttate psoriasis [2, 120-122].  
Given the involvement of the superantigen toxins secreted by Staphylococcus aureus and 
Streptococcus pyogenes in human illnesses, there has been considerable interest in the 
development of assays to detect either the toxin genes or proteins. An assay that could detect 
the presence of multiple superantigens in clinical samples or in the food supply would allow for 
improved diagnosis in patients with clinical signs of disease or for improved safety of food sources. 
Here I report the development of a method for multiplex detection of three staphylococcal (SEA, 
SEB, TSST-1) and two streptococcal toxins (SpeA and SpeC), which could be used for detecting 
toxins in food, in supernatants derived from blood cultures of Staphylococcus aureus and/or 
Streptococcus pyogenes, or directly in clinical samples. 
Traditionally, PCR [123-125] and ELISAs using monoclonal and/or polyclonal anti-toxin 
antibodies [126, 127] have been the method of choice for toxin detection and identification. Anti-
toxin antibodies were also used for toxin detection by double immunodiffusion, enzyme linked 
fluorescence assay (ELFA) [128] and flow cytometry [129]. Although PCR serves as a potential 
diagnostic method with high sensitivity, it does not provide information about the level of the 
toxins. For example, it is well known that different SAgs can vary in levels by orders of magnitude 
depending on post-transcriptional control [18]. In this regard, SEB and TSST-1 have been shown 
to be highly upregulated at the protein level compared to many other SAgs. Hence, methods that 
detect and quantitate the level of the pathogenic agent (i.e. the protein) provide a direct correlate 
of disease caused by that agent.  In addition, whereas the bacterial organism can be at low levels 
or even absent, (e.g. due to clearance by the immune system), the toxins are extremely stable 
and can persist in tissues. 
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Several investigators have demonstrated that ELISAs can detect staphylococcal toxins 
with good sensitivity [130-132], although concerns have been raised due to non-specific proteins 
in bacterial culture supernatants (e.g. such as Protein A that binds to IgG or naturally occurring 
peroxidases in food) [128, 130]. Commercial kits based on ELISA and ELFA using anti-
enterotoxin antibody or antibody fragments (Fab, “Fragment antigen binding”) are available with 
reported sensitivities for staphylococcal enterotoxins A-E of 0.25 to 1 ng/ml. To date, such assays 
are limited to analysis of individual toxins [116, 133].  
In the present study, I took advantage of ultra-high-affinity detecting agents that have been 
individually engineered in our laboratory for high-affinity binding to SEA, SEB, TSST-1, SpeA and 
SpeC [33-35, 134]; [Wang & Kranz, Unpublished]. The detecting agents represented the 
extracellular domain (12kDa) of the normal receptor for the SAgs, the variable domain of the beta 
chain of the T-cell receptor (Vβ). The collection of five Vβ domains had been engineered, using 
yeast display and directed evolution, to have ~1,000- to 3 million-fold increases in affinity for the 
cognate toxins [100, 135].  In this chapter, these five high-affinity Vβ proteins (FL, G5-8, D10V, 
KKR and HGSM) were further engineered to contain a C-terminal peptide sequence that allowed 
site-specific biotinylation. The five biotinylated proteins were immobilized on streptavidin coated, 
fluorescent-labeled beads to enable high-affinity, specific binding to their respective SAgs.  Bound 
SAgs were detected with commercially available polyclonal reagents, followed by fluorescent-
labeled detecting agents. Individual assays for each toxin were developed (referred to as 
singleplex assays, hereafter), which allowed specific and sensitive detection (SD50) at 400 pg/ml 
SEA, 3 pg/ml SEB, 25 pg/ml TSST-1, 6300 pg/ml SpeA and 100 pg/ml SpeC. These sensitivities 
were on the order of 4 to 80 fold higher than observed with standard ELISAs using the same 
reagents. 
For comparison, direct coupling of the G5-8 protein to paramagnetic beads yielded a 
detection sensitivity of 125 pg/ml SEB in different food matrices [133]. I hypothesized that site-
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specific biotinylation of high-affinity Vβ proteins would allow their immobilization on streptavidin 
pre-coated beads in an optimal orientation, thus improving the sensitivity. Indeed, the biotin 
approach yielded a 40-fold improvement to 3 pg/ml.  
In order to detect and quantitate multiple toxins in the same sample, I also developed a 
multiplex format of the assay. Although this format showed reduced sensitivity due to higher noise 
associated with the use of multiple polyclonal agents, the sensitivities were still well within the 
range necessary for detection in food sources or for rapid detection of toxins in bacterial cultures. 
For example, the assay allowed specific detection and also quantitative determination of 
staphylococcal SAgs SEA, SEB and TSST-1 in supernatants derived from cultures of 18 strains 
of Staphylococcus aureus. Thus, these reagents and the flow cytometry-based platform can be 
used for simultaneous detection of these toxins in food sources, or culture supernatants of 
potential pathogenic strains of Staphylococcus aureus and Streptococcus pyogenes.  
 
Materials and Methods 
Cloning, expression, and purification of high-affinity Vβ proteins in E. coli 
The genes encoding high-affinity Vβ proteins (FL, G5-8, D10V, KKR and HGSM) were 
cloned with a N-terminal 6X-His tag and a C-terminal Avitag (Avidity, LLC) in pET28a expression 
vector (Novagen), either including or excluding thrombin cleavage site between 6X His-tag and 
the Vβ sequence. For protein expression, Vβ containing pET28a constructs were transformed 
into E.coli BL21 (DE3) cells by heat shock method. Small scale cultures were induced for 4 hours 
at 37⁰C with 1mM IPTG. Protein expression in the lysates of uninduced and induced cultures was 
analyzed on Coomassie brilliant blue stained, 4-20% SDS-PAGE gels. Inclusion bodies were 
harvested from induced BL21 cells lysed by microfluidizer, washed using cold buffer (20 mM Tris, 
pH 8.0; 2.5 mM EDTA) and stored at -80⁰C.  
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For refolding, frozen aliquots of inclusion bodies were thawed to room temperature and 
solubilized with guanidine-HCl and β-mercaptoethanol. Solubilized inclusion bodies were 
analyzed on 4-20% SDS-PAGE gel and refolded by slow dilution. Refolded Vβ were purified using 
Ni-NTA agarose resin (Qiagen) followed by HPLC (Biocad Sprint), using a Superdex 200, size 
exclusion column (GE Healthcare), as described previously [33]. A gel filtration standard (Biorad) 
was used to track the purification of monomeric fractions of refolded, high-affinity Vβ proteins. 
In vitro biotinylation of purified Vβ proteins 
Monomeric fractions of refolded proteins were biotinylated at the specific lysine residue in 
the C-terminal Avitag sequence (GGGLNDIFEAQKIEWHE), using BirA enzyme (Avidity, LLC) 
overnight at 4C. Excess biotin was removed and biotinylation buffer was exchanged to 1X PBS, 
pH=7.4 using Zeba spin columns (Thermo Fisher Scientific Inc). Biotinylation was assessed by 
incubating the proteins with streptavidin and analyzing their change in mobility (“gel-shift”) on 4-
20% polyacrylamide gels. Biotinylated and unbiotinylated proteins were quantified by BCA Protein 
Assay kit (Thermo Fisher Scientific Inc). 
Pilot, singleplex assays for toxin binding by Vβ coated beads 
Biotinylated, high-affinity Vβ proteins (KKR, D10V, HGSM, G5-8 and FL) were immobilized 
on fluorescent, yellow, polystyrene beads (P2, P6, P8, P10 and P12 respectively, λemission = 525 
nm) that contained covalent-linked streptavidin (Spherotech, Inc.) overnight at 4⁰C. Once biotin-
Vβ was immobilized on the beads, unbound protein was washed away and the Vβ immobilized-
beads were incubated with 50 µl of 50 nM cognate, recombinant toxin solutions (SpeA, TSST-1, 
SpeC, SEB and SEA respectively) (Toxin Technology, Inc.) for 1.5-2 hours at 4⁰C. After washing, 
biotin-Vβ beads were incubated with 50 µl of 1:100 or 1:1000 dilution of rabbit anti-toxin polyclonal 
antibodies from rabbit (anti-SpeA, Abcam; anti-TSST-1, Abcam; anti-SpeC, Abcam; anti-SEB, 
Pierce and anti-SEA, whole antiserum, Sigma-Aldrich respectively] for 45-60 minutes at 4⁰C. After 
washing, the biotin-Vβ beads were incubated with 1:100 dilution of goat-anti rabbit IgG(H+L) 
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labelled with Alexa fluor 647 (Life Technologies). After 45-60 minutes, the beads were washed 
and bound toxins were detected by flow cytometry as an increase in signal in the appropriate 
fluorescence channel (λemission of Alexa fluor 647= 688 nm) by Accuri C6 flow cytometer (BD 
Biosciences). The fluorescence emitted by the yellow beads themselves was also recorded 
(λemission = 525 nm). 1X PBS + 2% BSA was used for diluting all reagents and washing the beads. 
Cross-reactivity of Vβ proteins engineered from the same template proteins, towards non-cognate 
toxin in singleplex assays 
For assessing cross-reactivity of KKR and G5-8 (both engineered from mVβ8.2) toward 
SEB and SpeA respectively, biotinylated KKR and G5-8 coated beads were incubated with either 
SpeA or SEB solution. After 60 minutes, the biotin Vβ-beads were washed and incubated with 
1:100 dilution of rabbit anti-SpeA or anti-SEB. After 60 minutes, the beads were washed with 
1:100 dilution of goat-anti rabbit IgG (H+L) labelled with Alexa-647. After washing, bead-bound 
toxins were detected as an increase in signal in fluorescence in appropriate fluorescence channel 
(λemission of Alexa fluor 647= 688 nm) by flow cytometry. Since anti-SpeA couldn’t detect SpeA 
bound to KKR coated beads efficiently and anti-SEB was found to contain antibodies that cross-
reacted with the structurally similar SpeA, hence anti-SEB was used for SpeA detection in future 
experiments. 
Similarly, for assessing cross-reactivity of D10V and HGSM (engineered from hVβ2.1) 
toward SpeC and TSST-1 respectively, biotinylated D10V and HGSM coated beads were 
incubated with various concentrations of either SpeC or TSST-1 solution. After 60 minutes, the 
biotin Vβ-beads were washed and incubated with 1:100 dilution of rabbit anti-SpeC or anti-TSST-
1. After 60 minutes, the beads were washed followed by incubation with 1:100 dilution of goat-
anti rabbit IgG (H+L) labelled with Alexa-647. After washing, bead-bound toxins were detected as 
an increase in signal in fluorescence in appropriate fluorescence channel (λemission of Alexa fluor 
647= 688 nm) by flow cytometry. 
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Comparing the efficiency of using fluorescently labeled, rabbit anti-toxin antibody versus 
unlabeled rabbit anti-toxin antibody for toxin detection  
To prevent the interference that could be caused due to the fluorescent-goat-anti rabbit 
IgG reagent while detecting toxins in rabbit serum, and also to reduce the number of incubation 
steps in the assay, I attempted fluorescent-labeling of anti-TSST-1 and using it for TSST-1 
detection. APEX™ Alexa Fluor® 647 Antibody Labeling Kit (Life Technologies) was used for 
covalently labeling anti-TSST-1 antibody with Alexa Fluor® 647 dye at its primary amine residues 
through succinimidyl ester linkage.  
For comparing unlabeled or labeled anti-TSST-1 in detection of TSST-1, biotinylated D10V 
coated beads were incubated with various concentrations of TSST-1. After 60 minutes, the beads 
were washed and incubated with 1:100 dilution of rabbit anti-TSST-1 (either unlabeled or labeled 
with Alexa-647). After 60 minutes, washed beads were incubated with either 1:100 dilution of 
goat-anti rabbit IgG (H+L) labelled with Alexa-647 or buffer (1X PBS + 2% BSA). After 60 minutes, 
the beads were washed and bound TSST-1 was detected as an increase in signal in fluorescence 
in appropriate fluorescence channel (λemission of Alexa fluor 647= 688 nm) by flow cytometry.  
Detection of TSST-1 in pooled, human serum by singleplex assay  
To assess if this strategy could be used in detecting toxins in serum, biotinylated D10V 
coated beads were added to various dilutions of TSST-1 prepared in 0, 0.1, 1 and 10% pooled, 
human serum (Sigma-Aldrich). After 60 minutes, the beads were washed and incubated with 
1:100 dilution of rabbit anti-TSST-1. After 60 minutes, washed beads were incubated with 1:100 
dilution of goat-anti rabbit IgG (H+L) labelled with Alexa-647 or buffer (1X PBS + 2% BSA). After 
60 minutes, the beads were washed and bound TSST-1 was detected as an increase in signal in 
fluorescence in appropriate fluorescence channel (λemission of Alexa fluor 647= 688 nm) by flow 
cytometry.  
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Effect of varying coating density of biotin-Vβ proteins and biotin in the assay 
Relative to the binding capacity of streptavidin beads, different amounts of biotin-Vβ (FL, 
G5-8, D10V, KKR and HGSM) were immobilized on streptavidin beads to determine optimum 
density of each biotin-Vβ on the bead surface that yielded minimum background and maximum 
sensitivity. Unbound proteins were washed away, and any unoccupied sites on Vβ coated, 
streptavidin beads were blocked with 7.5 mM free biotin (Sigma-Aldrich), to assess the effect of 
blocking on signal: noise in the assay. After washing, the beads were incubated with different 
concentrations of cognate, recombinant toxin solutions (SEA, SEB, TSST-1, SpeA and SpeC 
respectively). After 60 minutes, the beads were washed and incubated with 1:100 dilution of rabbit 
anti-toxin polyclonal antibodies (anti-SEA, anti-SEB, anti-TSST-1, anti-SEB and anti-SpeC 
respectively). After 60 minutes, the washed beads were incubated with 1:100 dilution of goat-anti 
rabbit IgG (H+L) labelled with Alexa fluor 647 (Life Technologies). After washing, toxins bound to 
the beads were detected as an increase in signal in fluorescence in appropriate fluorescence 
channel (λemission of Alexa fluor 647= 688 nm) by flow cytometry.  
Toxin binding titration with Vβ coated beads in singleplex format 
Biotinylated, high-affinity Vβ proteins (FL, G5-8, D10V, KKR and HGSM) were immobilized 
on streptavidin beads at optimum densities determined in preliminary experiments. Once biotin-
Vβ was immobilized on the beads, unbound protein was washed away and any unoccupied biotin 
binding sites were saturated by incubation with 7.5 mM free biotin, which was 1000 times excess 
than the available biotin binding sites on the streptavidin beads. After blocking with excess biotin, 
Vβ immobilized-beads were washed and incubated with various concentrations of recombinant 
toxins (SEA, SEB, TSST-1, SpeA or SpeC). After 60 minutes, the beads were washed and 
incubated with 1:100 dilution of rabbit anti-toxin polyclonal antibodies (anti-SEA, anti-SEB, anti-
TSST-1, anti-SpeC). In preliminary experiments, anti-SEB was found to contain antibodies that 
cross-reacted with the structurally similar SpeA, hence it was used for SpeA detection. After 
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washing, the biotin-Vβ beads were incubated with 1:200 dilution of goat-anti rabbit IgG(H+L) 
labelled with Alexa fluor 647 (Life Technologies). After 45-60 minutes, the beads were washed 
and bound toxins were detected by flow cytometry as an increase in signal in the appropriate 
fluorescence channel (λemission of Alexa fluor 647= 688 nm).  All assays with the five different Vβ 
proteins were quantitatively validated in singleplex format prior to use in multiplex format. 
Toxin binding titration by high-affinity Vβ in capture ELISA 
High-affinity Vβ proteins FL, G5-8, D10V, KKR and HGSM were immobilized on the wells 
of an ELISA plate at 5 µg/ml, overnight at 4⁰C. Unbound proteins were washed away with 1X PBS 
+ 0.1% Tween-20, and any unoccupied sites on the wells were blocked with blocking buffer (1X 
PBS + 1% milk). Vβ molecules immobilized on the wells were used to “capture” various 
concentrations of recombinant toxins (SEA, SEB, TSST-1, SpeA and SpeC respectively). After 
washing, 50 µl of 1:100 dilution of rabbit anti-toxin polyclonal antibodies (anti-SEA, anti-SEB, anti-
TSST-1, anti-SEB and anti-SpeC respectively) were added to the wells, followed by washing and 
incubation with 1:2000 dilution of goat-anti rabbit IgG(H+L) labelled with HRP (Sigma-Aldrich). 
After washing the wells twice, TMB substrate (KPL, Inc.) was added and the colorimetric reaction 
catalyzed by HRP was allowed to proceed for ~ 2 minutes, after which it was stopped by addition 
of 1N H2SO4 to yield a yellow colored product whose absorbance was measured at 450 nm using 
a plate reader (Biorad). Toxin titrations were performed in duplicate, to determine sensitivity of 
toxin detection by each Vβ in capture ELISA format. 
Toxin detection with mixtures of Vβ immobilized-beads in multiplex format 
Biotinylated, high-affinity Vβ proteins (FL, G5-8, D10V, KKR and HGSM) were immobilized 
on individual fluorescent polystyrene beads (P12, P10, P6, P2 and P8 respectively, each having 
unique fluorescence in the FL-1 channel (λemission of yellow beads= 525 nm) that contained 
covalently linked streptavidin (Spherotech, Inc.). After blocking with excess biotin, the Vβ 
immobilized-beads were washed, combined and incubated with various recombinant toxins at 
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different concentrations or culture supernatants from strains of Staphylococcus aureus. After 60 
minutes, beads were washed and incubated with a mixture of rabbit anti-toxin polyclonal 
antibodies (1:100 dilution), followed by washing and incubation with 1:200 dilution of goat-anti 
rabbit IgG(H+L) labelled with Alexa fluor 647 (Life Technologies). After 45 minutes, the beads 
were washed and bound toxins were detected as an increase in signal in the appropriate 
fluorescence channel (λemission of Alexa fluor 647= 688 nm), while the identity of the specific toxin 
was established by determining the fluorescent bead(s) (in the spectrally distinct, FL-1 channel; 
λemission = 525 nm). 
Culture of various strains of S. aureus 
Eighteen strains of S. aureus used in this work were purchased from the Network on 
Antimicrobial Resistance in Staphylococcus aureus (NARSA), now BEI Resources 
(http://www.beiresources.org/). Strains were grown by Micromyx, LLC (Kalamazoo, MI) in Todd 
Hewitt Broth (THB) for 16-20 hours with shaking at 200 rpm at 37°C. After incubation, cultures 
were centrifuged at 5,000 x g for 10 minutes to pellet the cells. The supernatant was passed 
through a 0.2 µm filter to obtain cell free supernatant.  Supernatants were stored at -20°C, prior 
to using in multiplex assays. 
 
Results 
Design of the bead-based two-color flow cytometry assay 
The bead-based multiplex assay took advantage of a panel of streptavidin coated 
polystyrene beads (P2, P6, P8, P10, P12), each with distinct fluorescence intensities in FL-1 
channel (λemission = 525 nm) (Fig. 3.1). Each type of bead was used to immobilize a single, purified 
high-affinity Vβ protein with covalently linked biotin. The high-affinity Vβ proteins (FL, G5-8, D10V, 
KKR and HGSM) served to “capture” the specific toxin (SEA, SEB, TSST-1, SpeA and SpeC) 
against which they were engineered. KKR and D10V also have low affinities for the structurally 
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related SAgs SEB and SpeC, respectively [33-35, 134]; [Wang & Kranz, Unpublished]. The 
“captured”, bead-bound toxins were detected by use of rabbit polyclonal anti-toxin antibodies 
followed by a fluorescent-labeled (Alexa fluor 647) goat-anti rabbit IgG.  
The use of both the single Vβ agents and the polyclonal reagents each provided an 
opportunity for specificity in the assays. Two-color flow cytometry allowed the fluorescence 
emitted by the fluorophore within each class of beads (λemission = 525 nm, FL-1 channel) to be 
distinguished from the fluorescence due to the bound toxin (λemission = 688 nm, FL-4 channel). This 
design allowed identification of the toxin by association with the specific Vβ-immobilized bead, 
and quantification of the amount of toxin by the level of fluorescence from the Alexa fluor 647 
reagent (Fig. 3.1, lower panel).  
Cloning, expression, and purification of high-affinity Vβ proteins from E. coli 
In order to generate bead-based arrays of high-affinity capture agents, the genes encoding 
six high-affinity Vβ proteins (FL, G5-8, L3, TSST-1, KKR and HGSM) (Fig. 3.2) were cloned with 
an N-terminal 6X-His tag for purification and a C-terminal ‘Avitag’ sequence 
(GGGLNDIFEAQKIEWHE) for enzymatic linkage of biotin to lysine. Initial cloning efforts involved 
cloning sequences encoding D10V and FL in pET28a as an NcoI and XhoI fragment, hence 
including a thrombin cleavage site between N- terminal 6X-His tag and Vβ sequence. In order to 
avoid removal of His tag from the proteins during storage, all Vβ sequences were later cloned 
excluding thrombin cleavage site. However, it was noted during test inductions as well as large 
scale expression in E.coli that the yield of G5-8 and L3 was reduced when thrombin cleavage site 
was absent, compared to when it was present between the 6X His-tag and the Vβ sequence (Fig. 
3.3. 3.4, Table 3.1). The sequences encoding G5-8 and L3 were later cloned in pET28a including 
thrombin cleavage site between 6X His-tag and the Vβ sequence, which resulted in increases in 
the yield of inclusion bodies (Fig. 3.4, Table 3.1). Although the exact reason behind the differences 
in protein expression of G5-8 and L3 proteins in the presence or absence of thrombin cleavage 
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site was not explored, it could be because of instability of corresponding mRNA or protein 
sequence or ineffective transcription/translation processes.  
High-affinity Vβ proteins purified as inclusion bodies from E.coli (Fig. 3.4) were subjected 
to refolding in vitro. Ni-affinity purified proteins were subjected to S200 gel filtration 
chromatography monomeric fractions of refolded Vβ (~15 to 18 kDa apparent mobility) were 
purified (Fig. 3.5). As evidenced in the chromatogram, D10V eluted as a mixture of primarily 
monomeric, but also dimeric species that presumably arose due to interactions between 
hydrophobic side chains of the two D10V molecules, which were noted to be 5Å apart in the 
crystal structure. 
In vitro biotinylation of purified V proteins 
Monomeric fractions of purified Vβ proteins were concentrated and subjected to 
biotinylation by incubating with BirA ligase and 100 µM biotin. To estimate the fraction of Vβ 
protein that was biotinylated, a gel-shift assay was used. The assay took advantage of the 
observation that biotin remains bound to streptavidin (SAv) even under SDS-PAGE conditions. 
Over 80% biotinylation of each of the Vβ proteins was evidenced by the disappearance of the 
majority of the Vβ-biotin species (~15 kDa band) in the presence of SAv (Fig. 3.6). The emergence 
of a molecular weight species of approximately 70 kDa was presumably due to the migration of 
the Vβ-biotin (~ 15 kDa) complexed with tetrameric streptavidin (~ 55 kDa), which is structurally 
more compact (and hence migrates faster on SDS-PAGE) than the higher molecular weight bands 
(100-130 kDa) which could correspond to unbound streptavidin tetramers, or aggregates of 
streptavidin tetramers [136, 137].  
To test that the biotinylated Vβ proteins could be immobilized on streptavidin beads, the 
proteins were incubated with streptavidin-coated beads at 4 ⁰C, overnight. On the next day, the 
beads were centrifuged and the protein left in supernatant was analyzed on a 4-20% SDS-PAGE 
gel (Fig. 3.7). The decrease in amount of protein in the supernatant, compared with the initial 
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amount that was added to beads, indicated that the biotin-Vβ was indeed immobilized on 
streptavidin coated beads. 
Pilot, singleplex assays for toxin binding by Vβ coated beads 
In a pilot flow cytometry assay, Vβ-immobilized fluorescent beads (P2-KKR, P6-D10V, P8-
HGSM, P10-G5-8 and P12-FL; λemission of yellow beads = 525 nm; fluorescence measured in FL-
1 channel) were incubated with 50 nM cognate toxin (SpeA, TSST-1, SpeC, SEB and SEA 
respectively), followed by washing and incubation with 1:100 or 1:1000 dilutions of rabbit anti-
toxin polyclonal antibodies (anti-SEA, anti-SEB, anti-TSST-1, anti-SpeA and anti-SpeC 
respectively). After washing, the beads were incubated with 1:100 dilution of goat-anti rabbit 
IgG(H+L) labelled with Alexa fluor 647 (λemission of Alexa fluor 647= 688 nm; measured in FL-4 
channel). After washing, fluorescence emitted by the beads was measured in both FL-1 and FL-
4 channels and analyzed on one-dimensional histograms as well as two-dimensional scatter plots 
(Fig. 3.8 and 3.9). Toxin binding by biotin-Vβ coated beads was detected as an increase in 
fluorescence in the FL-4 channel, compared to when no toxin was added to the beads (Fig. 3.8 
and 3.9, right panel). As expected, the fluorescence in FL-1 channel (emitted by the beads 
themselves) was not affected by the presence or absence of toxin (Fig. 3.8 and 3.9, left panel). 
Since, fluorescent signal in FL-4 channel due to toxin binding was higher when 1: 100 dilution of 
anti-toxin antibodies was used, this dilution was used in future experiments in anticipation that it 
will lead to higher sensitivity. 
It was also noted that the fluorescence signal arising due to SpeA binding by KKR coated 
beads was very weak compared to other Vβ coated beads binding to their cognate toxins (Fig. 
3.8, top panel and Fig. 3.10, panel A). This probably was due to poor affinity of anti-SpeA 
preparation to SpeA.  Owing to the structural similarity between SpeA and SEB, I predicted that 
polyclonal anti-SEB might contain antibodies that could cross-react with SpeA. Upon testing, flow 
cytometry experiments indicated that anti-SEB indeed contained antibodies that in fact bound 
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SpeA better than the anti-SpeA preparation (Fig. 3.10). Hence, polyclonal anti-SEB was used for 
SpeA detection in future experiments.  
While testing for the presence of antibodies in polyclonal anti-SEB that could cross-react 
with SpeA, it was found that the anti-SEB also contained antibodies that could bind to the 
structurally related superantigen SEC3, although the binding to SEC3 was several fold lower than 
binding to SpeA (Fig. 3.11). Accordingly, SEC3 detection by L3 coated on P4 beads, was 
excluded from multiplex assays since a rabbit anti-SEC polyclonal antibody was not available.  In 
addition, it was found that the fluorescence emitted by P4 beads overlapped with fluorescence 
emitted by P2 and P6 beads that would have further resulted in difficulties in establishing toxin 
identity.  
Cross-reactivity of Vβ proteins engineered from the same template proteins, towards non-cognate 
toxin in singleplex assays 
It has been previously demonstrated that G5-8 and KKR (both engineered from mVβ8.2 
for binding with high affinity to SEB and SpeA respectively) cross-react at lower levels with SpeA 
and SEB, respectively (KD ~ 5 nM and 68 nM respectively) [35]. This cross-reactivity was also 
observed in the assays when anti-SEB was used for detection of bound toxins, but not with anti-
SpeA probably because the polyclonal anti-SpeA reagent used did not contain sufficient 
antibodies that bound to SEB (Fig. 3.10). Similarly, I also noted that D10V and HGSM (engineered 
for binding with high affinity to TSST-1 and SpeC respectively) exhibited cross-reactivity toward 
SpeC and TSST-1, respectively (Fig. 3.12), probably because TSST-1 and SpeC both bind to the 
same human Vβ region, Vβ2.1, and the fact that D10V and HGSM were both engineered from 
the human Vβ2.1 mutant EP-8 that binds to both SAgs [34]. However, as indicated in the 
histograms, TSST-1 binding by bead-bound D10V was at least 2000-fold higher than bead-bound 
HGSM. Similarly, SpeC binding by bead-bound HGSM was at least 200-fold higher than bead-
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bound D10V (Fig. 3.12). Thus, a high degree of specificity could be realized at the expected 
physiological concentrations of these toxins. 
Comparing the efficiency of using fluorescently labeled, rabbit anti-toxin antibody versus 
unlabeled rabbit anti-toxin antibody for toxin detection 
During assay development, I attempted to directly label the rabbit anti-toxin antibody (here, 
anti-TSST-1) with a fluorophore (Alexa Fluor® 647 dye) to use it for toxin detection, (rather than 
the goat-anti rabbit IgG (H+L) labelled with Alexa-647). This modification in the assay would have 
not only reduced the time required for the assay, but would have allowed toxin detection in rabbit 
serum samples, since rabbits are often used in models of S. aureus. However, it was noted that 
the fluorescence signal arising due to TSST-1 binding by D10V coated beads was substantially 
reduced when fluorescent-labeled anti-TSST-1 was used compared to unlabeled anti-TSST-1, 
probably because of inefficient labeling and/or inactivation of the protein during the labeling 
reaction (Fig. 3.13). Because of this reduced sensitivity, direct fluorescent-labeled anti-toxin 
antibodies were not used further for toxin detection. 
Detection of TSST-1 in pooled, human serum by singleplex assay 
To assess if the assay could also be used for toxin detection in blood or serum samples, 
a singleplex assay was set up with biotin-D10V beads and anti-TSST-1 for detecting TSST-1 in 
various dilutions of TSST-1 prepared in 0, 0.1, 1 and 10% commercially available, pooled, human 
serum.  It was noted that the sensitivity of TSST-1 detection was reduced by about 100 fold in 
10% serum, compared to when TSST-1 dilutions were made in buffer (Fig. 3.14). The reduction 
in sensitivity was presumably due to pre-existing anti-TSST-1 antibodies in the serum [138, 139], 
which competed with bead-bound D10V for binding to TSST-1. With this method, ~10 ng/ml 
TSST-1 could be detected in undiluted pooled human serum indicating that the sensitivity of this 
assay would vary in human serum samples depending on the prior exposure of individuals to 
these toxins.  
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Effect of varying coating density of biotin-Vβ proteins and blocking with biotin  
To study how the density of biotin-Vβ molecules on streptavidin bead surface would affect 
sensitivity of toxin detection, different amounts of biotin-Vβ molecules were immobilized on the 
bead surfaces. Such beads with different Vβ coating densities (1X, 2X or 5X, relative to the binding 
capacity of the beads) were then tested for binding to different concentrations of cognate toxins 
in singleplex assays. As indicated in figure 3.15, the signal arising due to toxin binding was often 
reduced when excess biotin-Vβ was added to the beads. It is possible that once the streptavidin 
binding sites on beads were saturated, excess Vβ molecules adsorbed non-specifically, or were 
present at low levels after washing. These weakly bound or free biotin-Vβ molecules could 
possibly compete for toxin binding with the bead-bound biotin-Vβ molecules, hence resulting in 
decreased signal.  
To ensure that the polyclonal reagents used in the assays did not bind non-specifically to 
the bead surface, the bead surface was saturated with excess biotin (~1000 fold, compared to 
the binding capacity of the beads) after immobilizing biotin-Vβ molecules. Blocking of the unbound 
sites on bead surface with excess biotin resulted in a reduction in the background and an 
improvement in fluorescent signal due to toxin binding. Based on these experiments, optimum 
coating density of each biotin-Vβ was determined, and this along with blocking with excess biotin 
was used to obtain Vβ-coated beads with minimum background and maximum sensitivity of toxin 
detection. 
Sensitivity of toxin detection in singleplex assays 
After optimizing various parameters of the assays (e.g. concentrations of polyclonal 
reagents, biotin-Vβ coating densities on streptavidin bead surface, blocking with biotin etc.), each 
high-affinity Vβ was subjected to toxin binding titrations in singleplex, flow cytometry based assays 
for determining detection sensitivity for each toxin (Fig. 3.16 and 3.17). Each assay showed a 
dynamic range of over three orders of magnitude for determining concentrations of the specific 
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toxin. The range spanned the picogram to hundreds of nanograms per ml concentrations. Thus, 
each toxin detection assay exhibited linearity over a range of concentrations, which could be used 
to calculate concentrations of toxins in unknown samples (Fig. 3.18). As determined from the low 
end of the flow cytometry histograms (Fig. 3.16), the assay detection limits were approximately 
400 pg/ml SEA, 3 pg/ml SEB, 25 pg/ml TSST-1, 6000 pg/ml SpeA and 100 pg/ml SpeC.  
I compared the sensitivities of toxin detection in the flow-cytometry singleplex assays with 
a standard capture ELISA (where the Vβ proteins were adsorbed to 96-well plates, and detection 
was with the same polyclonal reagents as in the flow cytometry assay) (Fig. 3.19). Sensitivities of 
toxin detection by bead-based, singleplex/multiplex flow cytometry assays or by ELISAs, were 
calculated as the lowest toxin concentration at which the median fluorescence intensity or optical 
density was at least 3 standard deviations above the negative control. The detection limits in the 
capture ELISAs were 4 to 80 fold higher than in the flow cytometry assay (Table 3.2). I believe 
that the enhanced sensitivity is in part due to the greater surface density of properly arrayed Vβ 
domains on the beads compared to the adsorption of Vβ proteins, some in a non-binding 
configuration, to the wells of a 96-well microtitre plate. It is worth noting the lower sensitivity of 
SpeA detection in both the bead-based approach and in ELISAs, compared to all of the other 
toxins. I believe that this could have to do with the fact that I was unable to identify an optimal 
anti-SpeA polyclonal preparation and thus used a cross-reacting anti-SEB antibody preparation.  
Sensitivity of toxin detection and cross-reactivity in multiplex assays 
Given the remarkable sensitivity of toxin detection in singleplex assays, I examined the 
sensitivities when the five singleplex assays were combined to generate a multiplex assay. For 
assessing sensitivity of detecting each toxin in a multiplex assay, a mixture of biotin-Vβ coated 
beads were incubated with different concentrations of single toxin. After washing, bead-bound 
toxin molecules were detected with a mixture of polyclonal anti-toxin antibodies (Fig. 3.20). I noted 
that the sensitivity of toxin detection in multiplex assay reduced by 1 to 2 orders of magnitude 
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compared to the singleplex format, presumably due to the higher background “noise” associated 
with non-specific binding of Vβ-coated beads by the mixture of polyclonal antibodies (Table 3.3). 
The sensitivities of toxin detection by multiplex assay were approximately 10 ng/ml SEA, 0.1 ng/ml 
SEB, 0.1 ng/ml TSST-1, 10 ng/ml SpeA and 1 ng/ml SpeC, which were still within range for toxin 
detection in culture supernatants of Staphylococcus aureus strains (as described below).  
SEA and SpeA multiplex detection assays exhibited linearity up to 100 ng/ml, while SEB, 
TSST-1 and SpeC detection assays exhibited linearity up to 10 ng/ml, which could be used for 
estimating concentrations (Fig. 3.21). As seen in singleplex assays, bead-bound KKR (P2-KKR) 
cross-reacted with SEB (Fig. 3.20). Similarly, P8-HGSM cross-reacted with TSST-1 and P6-D10V 
cross-reacted with SpeC. SEA detection in multiplex format was most specific, since no cross-
reactivity of bead-bound FL protein with other toxins was detected in the assay. 
Detection and quantitation of multiple toxins in a multiplex assay 
In order to detect and quantitate multiple toxins in the same sample, multiplex assays with 
mixture of biotin-Vβ coated beads were performed. Solutions containing one toxin or combinations 
of two or more toxins were assayed in the multiplex format (Fig. 3.22 and 3.23). Although the 
maximum fluorescence intensity observed with individual detection system varied, the assay 
showed that in all cases the expected toxin was detected in the appropriate channel for that Vβ-
immobilized bead.  
Multiplex assay for detection of toxins in Staphylococcus aureus culture supernatants  
To validate the use of this assay for detection of toxins in potential clinical isolates or other 
unknown sources (Table 3.4), 18 strains of Staphylococcus aureus from the NARSA repository 
were cultured. The strains were chosen based on the known SAg gene expression profiles of at 
least some of them. The multiplex assay was performed with diluted culture supernatants (diluted 
1:4) from the 18 strains and the fluorescence intensity for each of the five Vβ systems was 
determined (Fig.3.24). Upon comparing the fluorescence intensity arising due to binding of 
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toxin(s) in supernatants with FL, G5-8 or D10V coated beads, approximate concentrations could 
be estimated based on linear regression using correlation curves shown in Fig. 3.21 (Table 3.5). 
In situations where fluorescence intensity was outside the linear range, estimation of toxin 
concentrations was performed using non-linear regression methods. 
The results showed that 12 of the 18 strains expressed SEA, SEB and/or TSST-1 (note 
that some signal from KKR (V-SpeA) was present when SEB was detected due to its cross-
reactivity with SEB). SEB was expressed in four of the S. aureus strains (NRS100, NRS113, 
NRS114 and NRS387). TSST-1 was expressed in seven strains (NRS1, NRS2, NRS70, NRS111, 
NRS112, NRS651, and NRS701). Interestingly, five of the seven TSST-1 positive strains (NRS1, 
NRS2, NRS111, NRS112 and NRS651) also expressed significant levels of SEA. Estimated 
concentrations of toxins expressed in the supernatants of different strains ranged from 10 – 500 
ng/ml, depending on the toxin (Table 3.5). 
 
Discussion 
The varied clinical effects of the superantigens produced by Staphylococcus aureus and 
Streptococcus pyogenes has prompted considerable effort in the development of assays for their 
detection in food sources or in clinical samples. The approaches have included DNA-based 
systems such as PCR for gene detection and use of antibodies as probes for detections of the 
toxins themselves [123-127]. While PCR can provide a rapid and sensitive method for confirming 
the presence of genes encoding the toxin gene, this approach requires an adequate number of 
bacterial cells and it does not provide information about the level of the toxins that are in a sample. 
For example, tissue-localized organisms could serve as a reservoir for the toxins that are released 
into the blood stream. Alternatively, cultures derived from a sterilized food source may be negative 
but the sample could contain preformed, heat stable enterotoxins. Hence, I propose methods that 
detect the clinically relevant agent, the toxins, are a preferred approach.   
96 
 
In this study, highly sensitive, singleplex assays were developed for detection of five 
staphylococcal and streptococcal toxins that have been associated with human disease. The 
assays made use of high-affinity, in vitro engineered probes (a variable domain of the TCR β 
chain) for each of the toxins. The singleplex assays were combined to yield a multiplex assay that 
allowed reliable detection of the toxins in a single sample, including from culture supernatants of 
various S. aureus strains. 
The design of the singleplex assays involved the arraying of high-affinity Vβ proteins, using 
site-directed biotinylation. The streptavidin-bound Vβ domains served as a capturing agent for the 
toxin against which they were engineered [33-35, 135]; [Wang & Kranz, Unpublished]. 
Commercially available, polyclonal antibodies against the toxins served as the detecting agents. 
By way of comparison, the assay used in the present study with biotinylated G5-8 coated 
streptavidin beads enabled detection of SEB at concentrations as low as 3 pg/ml in singleplex 
assay. This was 40 fold better than previous effort from our lab of detecting SEB where G5-8 was 
coated on paramagnetic beads by means of amine coupling [32] (0.125 ng/ml SEB in Tallent et 
al. 2013).  I believe that the site-specific biotinylation of Vβ protein allowed its immobilization on 
streptavidin coated in an optimal orientation hence leading to improved sensitivity of toxin 
detection, than immobilizing Vβ via amine coupling methods which may have yielded 
heterogeneous orientations. 
Another factor that I believe contributed to the high sensitivity of SEB detection in 
singleplex assay was the remarkably high affinity of the engineered G5-8 protein for SEB (KD = 
50 pM) [34]. In fact, the detection sensitivities for the other toxins in the singleplex assays, i.e. 
TSST-1 (25 pg/ml), SpeC (100 pg/ml), SpeA (6300 pg/ml) and SEA (400 pg/ml) also appeared to 
correlate to some extent with the affinities of the Vβ domains for their respective toxins: D10V (KD 
= 50 pM), HGSM (KD = 500 pM), KKR (KD = 270 pM), and FL (KD = 4 nM) (Table 3.6)  [33,35,36]. 
I suggest that the exception, lower sensitivity of SpeA detection despite the relatively high affinity 
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of the KKR, was due to lack of a good, anti-SpeA polyclonal antibody, requiring us to use a cross-
reacting anti-SEB polyclonal antibody for SpeA detection. 
In addition to the contribution to the sensitivity of the singleplex assays, the use of two 
distinct toxin binding proteins (i.e., high-affinity Vβ proteins to capture the toxin and anti-toxin 
antibody to detect the “captured” toxin) provided additional specificity to the toxin detection.  In 
multiplex assay, some expected cross-reactivities identified in the singleplex format, were noted 
for high-affinity Vβ proteins which were engineered from same template Vβ (KKR and G5-8 
engineered from mVβ8 cross-reacted with SEB and SpeA respectively; HGSM and D10V 
engineered from hVβ2.1, cross-reacted with TSST-1 and SpeC respectively) (Fig. 3.20) [34, 35]  
The flow cytometry-based assays described here can be used to detect toxins in food 
sources or in culture supernatants of Staphylococcus aureus and/or Streptococcus pyogenes, or 
in clinical samples. Enterotoxins like SEA in contaminated food sources have been shown to be 
present in the range from 0.05 to 20 ng/g of food [131, 140]. In foods isolated from food poisoning 
outbreaks, staphylococcal enterotoxins (particularly, SEA, SEE and SEH) were reported in the 
range of 0.08 to 0.5 ng/ml [83, 84] and 0.36-20 ng/g [83, 86, 87, 117] . Importantly, these studies 
required concentration steps for the food sample in order to detect and quantitate the levels of 
the toxins that were recovered.  These assays reported assay sensitivities from ~ 0.1 - 0.5 ng/ml, 
similar to our singleplex assay for SEA (0.4 ng/ml SEA). However, our SEB and TSST-1 assays 
had sensitivities that were two orders of magnitude higher than these and other commercial 
assays [116, 128, 141, 142]. The possible linkage between SEA and TSST-1 expression among 
strains suggests that TSST-1 detection could be a biomarker for SEA, if the latter falls below the 
levels of detection.  
More recently, highly automated, DNA based tests have been developed for rapid 
identification of microorganisms from blood cultures of patients [143, 144]. Since these tests also 
provide information about antibiotic resistance of the microorganism present, they could guide 
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appropriate antibiotic treatment for patients. However in situations where a patient’s blood culture 
is negative for microorganisms, for example, in a case of deep tissue infection by Staphylococcus 
aureus or Streptococcus pyogenes, the patient could still develop shock-like or inflammatory 
symptoms that might arise due to the secretion of superantigenic toxins by the bacteria [145-147]. 
In such situations, or in cases when bacterial burden in blood is minimal, methods that detect the 
toxin directly could be useful.  
In this study, 18 strains of Staphylococcus aureus obtained from the NARSA repository 
were also examined for toxin secretion. The collection included several strains that were isolated 
from clinical samples. The supernatants from these cultures were analyzed by multiplex assay for 
simultaneous detection of SEA, SEB and TSST-1. The expression of the toxins was consistent 
with the presence of genes in strains for which genomic data was available, as in the case of 
NRS1 (entA (SEA) and tst (TSST-1)), NRS70 (tst (TSST-1)) and NRS100 (entB (SEB)). NRS22 
served as a negative control since it has been reported to lack the genes that encode SEA, SEB, 
and TSST-1. Complete absence of signal in five other strains (NRS382, NRS384, NRS667, 
NRS725, NRS741) supported the view that the assay was specific for the target toxins and did 
not yield false positives for unrelated proteins, such as Protein A expressed by S. aureus [128, 
130]. 
I also noted that five of the seven strains that expressed TSST-1 also expressed SEA. 
This toxin expression profile was particularly interesting because previous reports have linked 
SEA co-expression with TSST-1 in menstrual TSS, more often than in non-menstrual TSS [148, 
149]. In the collection of strains tested here, NRS112 (MN8) was isolated from a menstrual TSS 
patient and I detected both SEA and TSST-1 in the culture supernatant of this strain. Interestingly, 
other investigators detected the gene corresponding to SEA in this strain by PCR, but they could 
not detect the protein probably because the concentration of SEA secreted was very low [150]. 
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 The S. aureus strain NRS111 (FRI913) was obtained from a food poisoning outbreak, 
and it was thus not surprising that SEA was detected in the culture supernatant of this strain, 
since SEA has been incriminated in most S. aureus food poisoning outbreaks around the world 
[83, 84, 86-88]. I also detected TSST-1, which is not enterotoxic, although it could serve as a 
biomarker for the presence of S. aureus or possibly even SEA [4]. Investigators have confirmed 
the presence of sea and tst genes in this strain by PCR  [151]. Our detection of SEB in NRS114 
was also consistent with the presence of the seb gene by PCR [151]. 
In summary, I present here a sensitive flow cytometry-based assay for the detection of 
three staphylococcal and two streptococcal toxins using ultra-high-affinity Vβ proteins and 
polyclonal antibody reagents. Similar approaches can be used for the detection of other SAgs.  
Multiplex formatting of the assays, using beads with a range of fluorescent dyes, enabled 
simultaneous detection of SEA, SEB and TSST-1, in culture supernatants of several strains of S. 
aureus. I also reported that the multiplex assay could be used for detection of SpeA and SpeC 
toxins, for which no commercial assays are available yet.  
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FIGURES 
 
Fig. 3.1. Schematic representing the multiplex assay 
Yellow, streptavidin beads (P2, P6, P8, P10, and P12 --- with distinct fluorescence intensities in 
FL-1 channel, λemission = 525 nm) coated with biotinylated, high-affinity Vβ are added to an 
unknown solution, to determine the presence of SEA, SEB, TSST-1, SpeA and/or SpeC toxin. 
Polyclonal, rabbit anti-toxin antibodies bind to the toxins bound to the Vβ-coated beads; which 
are detected by goat-anti rabbit IgG labelled with Alexa fluor 647 (FL-4 channel, λemission = 688 
nm). Scatter plots in the presence or absence of toxin(s) are shown in the lower panel. An increase 
in fluorescence emitted by the beads in the FL-4 channel (Y-axis) indicates the presence of 
toxin(s) in the unknown sample. Since each class of beads emits distinct fluorescence in FL-1 
channel (X-axis), identity of the toxin present is established by identifying the specific, Vβ-
immobilized bead(s) undergoing an increase in fluorescence in the FL-4 channel (Y-axis). 
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Fig. 3.2 Sequences of Vβ proteins engineered for high affinity towards staphylococcal and 
streptococcal toxins 
Multiple sequence alignment between sequences of high-affinity Vβ proteins by Clustal 2.1 is 
shown. Genes encoding each high affinity Vβ proteins were cloned in pET28a vector with a N-
terminal 6X His tag (which aided in affinity purification) and a C-terminal Avitag (which allowed 
site-specific biotinylation).  
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Fig. 3.3. Test inductions indicating expression of high-affinity Vβ proteins from pET28a 
constructs  
Genes encoding high-affinity Vβ proteins were cloned in pET28a in two formats: (A) with thrombin 
cleavage site (T) between 6X His-tag and the Vβ sequence; (B) without thrombin cleavage site 
(NT) between 6X His-tag and the Vβ sequence. Transformed E.coli BL21 (DE3) cells were 
cultured for 4 hours, followed by induction for 4 hours with IPTG. Lysates of induced and 
uninduced cultures were analyzed on 4-20% SDS-PAGE gels for assessing protein expression. 
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Fig. 3.4. Large scale expression of high-affinity Vβ proteins as inclusion bodies, from E.coli 
High-affinity Vβ proteins were expressed as inclusion bodies in E.coli transformed with pET28a 
containing either thrombin cleavage site (T) between 6X His-tag and the Vβ sequence; or without 
thrombin cleavage site (NT) between 6X His-tag and the Vβ sequence. Solubilized inclusion 
bodies were analyzed on a 4-20% SDS-PAGE gel. 
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Fig. 3.5. Size exclusion chromatograms of refolded, high-affinity Vβ proteins  
In vitro refolded, high-affinity Vβ proteins were purified by affinity chromatography with Ni agarose; 
followed by size exclusion chromatography using a S200 column. Molecular weight standards 
(dashed line) was used to track the purification of monomeric fractions of refolded, high-affinity 
Vβ proteins. 
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Fig. 3.6. Gel-shift assay for assessing biotinylation of high-affinity Vβ proteins on SDS-
PAGE 
Monomeric fractions of high-affinity Vβ proteins were biotinylated at a specific lysine residue in 
Avitag sequence in vitro, by BirA enzyme. Biotinylation was assessed by analyzing change in 
mobility of biotinylated-Vβ (~15 kDa band), in the presence or absence of streptavidin (SAv) on 
4-20% SDS-PAGE gels. 
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Fig. 3.7. SDS-PAGE gels for assessing immobilization of high-affinity Vβ proteins on 
streptavidin beads 
2.5 μg of biotinylated D10V or FL protein was added to streptavidin beads and incubated 
overnight. Next day, supernatants (Sup) left from the reaction were loaded on a 4-20% SDS-
PAGE gels and compared with an equivalent amount of biotinylated protein. Reduction in intensity 
of biotin-Vβ band in “Sup” lanes indicated biotin-Vβ was immobilized on streptavidin beads. 
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Fig. 3.8. Pilot singleplex assays for detecting binding of high-affinity Vβ proteins to the 
toxins against which they were engineered 
Biotinylated, high-affinity Vβ proteins coated fluorescent streptavidin beads, were incubated with 
50 nM toxin against which they were engineered. Bound toxin was detected by rabbit anti-toxin 
polyclonal antibodies, followed by goat-anti rabbit IgG(H+L) labelled with Alexa fluor 647. 
Fluorescence in the absence of toxin, is represented by gray (filled) trace on each histogram. 
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Fig. 3.9. Pilot singleplex assays for detecting binding of high-affinity Vβ proteins to the 
toxins against which they were engineered 
Biotinylated, high-affinity Vβ proteins coated fluorescent streptavidin beads, were incubated with 
50 nM toxin against which they were engineered. Bound toxin was detected by rabbit anti-toxin 
polyclonal antibodies, followed by goat-anti rabbit IgG(H+L) labelled with Alexa fluor 647. Two-
dimensional scatter plots are shown, with fluorescence arising from beads on X-axis, and 
fluorescence arising due to toxin binding on Y-axis.  
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Fig. 3.10. Cross-reactivity of high-affinity Vβ proteins engineered from mVβ8.2, KKR and 
G5-8, to SEB and SpeA respectively 
Cross-reactivity of KKR to SEB, and G5-8 to SpeA was detected when anti-SEB was used to 
detect toxin binding (panels B & D), but not with anti-SpeA (panels A & C). Flow cytometry 
histograms for binding are shown. Fluorescence in the absence of toxin, is represented by gray 
(filled) trace on each histogram. 
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Fig. 3.11. Binding of mVβ8.2 derived, high-affinity proteins (KKR, L3, G5-8) to cognate 
toxins (SpeA, SEC3, SEB) can be detected using anti-SEB  
KKR, L3 and G5-8 were coated on individual, fluorescent streptavidin beads, followed by 
incubation with 10 nM SpeA, SEC3 and SEB respectively. Bound toxin in each case was detected 
as an increase in fluorescence, upon incubation with rabbit anti-SEB antibody, followed by 
washing and incubation with goat-anti rabbit IgG labelled with Alexa-647. Fluorescence in the 
absence of toxin, is represented by gray (filled) trace on each histogram. *** Note that the 
fluorescence in the absence of toxin is different for each Vβ, indicating that anti-SEB antibody 
(polyclonal) exhibited different degree of non-specificity towards each Vβ.  
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Fig. 3.12. Cross-reactivity of high-affinity Vβ proteins engineered from hVβ2.1, D10V and 
HGSM, toward SpeC and TSST-1 respectively 
D10V and HGSM were coated on individual, fluorescent streptavidin beads, followed by 
incubation with various concentrations of TSST-1 or SpeC. Bound toxin was detected as an 
increase in fluorescence, upon incubation with rabbit anti-TSST-1 or anti-SpeC antibody, followed 
by goat-anti rabbit IgG labelled with Alexa-647. Fluorescence in the absence of toxin, is 
represented by gray (filled) trace on each histogram.  
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Fig. 3.13. Comparing the efficiency of using fluorescently labeled, rabbit anti-toxin 
antibody (anti-TSST-1 here), versus unlabeled, rabbit anti-toxin antibody for toxin 
detection in singleplex assay 
(A) D10V coated P8 beads were added to different concentrations of TSST-1. Bound toxin was 
detected as an increase in fluorescence, upon incubation with unlabeled anti-TSST-1 antibody 
(rabbit), followed by goat-anti rabbit IgG labelled with Alexa-647; or with anti-TSST-1 antibody 
labeled with Alexa-647. Flow cytometry histograms for TSST-1 binding are shown. Fluorescence 
in the absence of toxin, is represented by gray (filled) trace on each histogram. (B) Comparison 
of efficiency of TSST-1 detection by fluorescently labeled anti-TSST-1 versus unlabeled anti-
TSST-1 antibody. Median fluorescence units from the histograms above, were used to generate 
the bar graph.  
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Fig. 3.14. Detection of TSST-1 in pooled, human serum by singleplex assay 
(A) D10V coated P4 beads were added to different dilutions of TSST-1 prepared in 0, 0.1, 1 and 
10% serum. Bound toxin was detected as an increase in fluorescence, upon incubation with rabbit 
anti-TSST-1 antibody, followed goat-anti rabbit IgG labelled with Alexa-647. Flow cytometry 
histograms for binding are shown. Fluorescence in the absence of toxin, is represented by gray 
(filled) trace on each histogram. (B) Median fluorescence units due to bound toxin were used to 
generate binding curves.  
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Fig. 3.15. Effect of varying coating density of biotin-Vβ on streptavidin bead surface, and 
blocking unoccupied sites with biotin 
Streptavidin beads were coated with different amounts of biotin-Vβ to yield different coating 
densities. Washed beads were incubated either with buffer, or with excess biotin to saturate any 
unbound sites. Such beads with different Vβ coating density (either blocked with biotin or not) 
were used to detect different concentrations of cognate toxins. Median fluorescence units from 
histograms were used to generate bar graphs. Fluorescence in the absence of toxin, is 
represented by gray bar.  
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Fig. 3.16. Toxin binding titration by biotinylated, high-affinity Vβ coated on fluorescent 
beads, in singleplex assays 
Each biotinylated, high-affinity Vβ protein, coated on fluorescent yellow, streptavidin beads was 
used to capture various concentrations of cognate, recombinant toxin. Bound toxins were 
detected by rabbit polyclonal anti-toxin antibodies, followed by goat-anti rabbit IgG labelled with 
Alexa fluor 647. Flow cytometry histograms for each binding titration are shown, with fluorescence 
arising due to toxin-binding on X-axis. Fluorescence in the absence of toxin, is represented by 
gray (filled) trace on each histogram. Data shown are representative of experiments performed in 
triplicate.  
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Fig. 3.16 (cont.). Toxin binding titration by biotinylated, high-affinity Vβ coated on 
fluorescent beads, in singleplex assays 
Each biotinylated, high-affinity Vβ protein, coated on fluorescent yellow, streptavidin beads was 
used to capture various concentrations of cognate, recombinant toxin. Bound toxins were 
detected by rabbit polyclonal anti-toxin antibodies, followed by goat-anti rabbit IgG labelled with 
Alexa fluor 647. Flow cytometry histograms for each binding titration are shown, with fluorescence 
arising due to toxin-binding on X-axis. Fluorescence in the absence of toxin, is represented by 
gray (filled) trace on each histogram. Data shown are representative of experiments performed in 
triplicate. 
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Fig. 3.17. Titration curves for binding of cognate toxins by biotinylated, high-affinity Vβ 
coated on fluorescent beads, in singleplex assays 
Median fluorescence units due to toxin binding (in FL-4 channel) from the histograms (shown in 
previous figure) were used to generate binding curves. Red, dashed line indicates fluorescence 
in the absence of toxin, in each case. Data shown are representative of experiments performed 
in triplicate. 
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Fig. 3.18. Toxin binding titration by biotinylated, high-affinity Vβ coated on fluorescent 
beads, in singleplex assays 
Median fluorescence units due to toxin binding (in FL-4 channel) from the histograms shown in 
figure 3.16, were used to generate bar graphs on the left. Black, dashed line indicates 
fluorescence in the absence of toxin, in each case. Data shown are representative of experiments 
performed in triplicate. Correlation plots shown on the right indicate the concentration range in 
which there was a linear correlation (R2 ~0.9), between fluorescence due to toxin binding (Y-axis) 
and toxin concentration (X-axis). 
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Fig. 3.18 (cont.). Toxin binding titration by biotinylated, high-affinity Vβ coated on 
fluorescent beads, in singleplex assays 
Median fluorescence units due to toxin binding (in FL-4 channel) from the histograms shown in 
figure 3.16, were used to generate bar graphs on the left. Black, dashed line indicates 
fluorescence in the absence of toxin, in each case. Data shown are representative of experiments 
performed in triplicate. Correlation plots shown on the right indicate the concentration range in 
which there was a linear correlation (R2 ~0.9), between fluorescence due to toxin binding (Y-axis) 
and toxin concentration (X-axis). 
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Fig. 3.19. Capture ELISA for staphylococcal or streptococcal toxin detection 
High-affinity Vβ proteins were immobilized on wells of an ELISA plate to capture various 
concentrations of cognate, recombinant toxins. Bound toxins were detected by polyclonal, anti-
toxin antibodies from rabbit, followed by goat-anti rabbit IgG-HRP. TMB substrate was added and 
the reaction was stopped with 1N H2SO4 to yield a yellow colored product. Absorbance at 450 nm 
(A450) was recorded and used to generate binding curves. Red, dashed line indicates 
absorbance in the absence of toxin. The error-bars represent standard deviations from two 
independent experiments. 
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Fig. 3.20. Toxin binding titration by biotinylated, high-affinity Vβ coated on fluorescent 
beads in multiplex format, indicating sensitivity and cross-reactivity 
Solutions containing different concentrations of toxins were added to a mixture of five fluorescent 
beads coated with five, high-affinity Vβ proteins. Bound toxins were detected upon incubation with 
a mixture of rabbit polyclonal, anti-toxin antibodies, followed by goat-anti rabbit IgG(H+L) labelled 
with Alexa fluor 647. Median fluorescence units (in FL-1 and FL-4 channels) from the beads were 
analyzed on a scatter plot. Bar graphs indicating fluorescence in FL-4 channel (due to toxin 
binding) exhibited by each Vβ coated bead are shown. Fluorescence emitted by KKR (Vβ-SpeA), 
D10V (Vβ-TSST-1), HGSM (Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown 
by red, blue, green, orange and purple bars respectively. Black, dashed line indicates 
fluorescence in the absence of toxin. Data shown are representative of two experiments. 
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Fig. 3.20 (cont.). Toxin binding titration by biotinylated, high-affinity Vβ coated on 
fluorescent beads in multiplex format, indicating sensitivity and cross-reactivity 
Solutions containing different concentrations of toxins were added to a mixture of five fluorescent 
beads coated with five, high-affinity Vβ proteins. Bound toxins were detected upon incubation with 
a mixture of rabbit polyclonal, anti-toxin antibodies, followed by goat-anti rabbit IgG(H+L) labelled 
with Alexa fluor 647. Median fluorescence units (in FL-1 and FL-4 channels) from the beads were 
analyzed on a scatter plot. Bar graphs indicating fluorescence in FL-4 channel (due to toxin 
binding) exhibited by each Vβ coated bead are shown. Fluorescence emitted by KKR (Vβ-SpeA), 
D10V (Vβ-TSST-1), HGSM (Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown 
by red, blue, green, orange and purple bars respectively. Black, dashed line indicates 
fluorescence in the absence of toxin. Data shown are representative of two experiments. 
 
  
123 
 
 
Fig. 3.20. (cont.). Toxin binding titration by biotinylated, high-affinity Vβ coated on 
fluorescent beads in multiplex format, indicating sensitivity and cross-reactivity 
Solutions containing different concentrations of toxins were added to a mixture of five fluorescent 
beads coated with five, high-affinity Vβ proteins. Bound toxins were detected upon incubation with 
a mixture of rabbit polyclonal, anti-toxin antibodies, followed by goat-anti rabbit IgG(H+L) labelled 
with Alexa fluor 647. Median fluorescence units (in FL-1 and FL-4 channels) from the beads were 
analyzed on a scatter plot. Bar graphs indicating fluorescence in FL-4 channel (due to toxin 
binding) exhibited by each Vβ coated bead are shown. Fluorescence emitted by KKR (Vβ-SpeA), 
D10V (Vβ-TSST-1), HGSM (Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown 
by red, blue, green, orange and purple bars respectively. Black, dashed line indicates 
fluorescence in the absence of toxin. Data shown are representative of two experiments. 
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Fig. 3.21. Linear correlation plots for toxin titration in multiplex format 
The concentration range in which there was a linear correlation (R2 ~0.9), between fluorescence 
due to toxin binding (Y-axis) and toxin concentration (X-axis) was plotted to generate correlation 
plots, which could be used for estimating concentrations of these toxins present in unknown 
samples.  
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Fig. 3.22. Detection of a single toxin by multiplex assay  
Solutions containing 50 ng/ml SEA, 10 ng/ml SEB, 10 ng/ml TSST-1, 50 ng/ml SpeA or 10 ng/ml 
SpeC were tested in  multiplex assays with the five fluorescent beads coated with five, high-affinity 
Vβ proteins. Fluorescence emitted by each Vβ-coated bead due to toxin binding, was plotted on 
bar graphs shown. In all cases, the toxins were detected by the beads immobilized with the high-
affinity Vβ engineered for that toxin. Fluorescence emitted by KKR (Vβ-SpeA), D10V (Vβ-TSST-
1), HGSM (Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown by red, blue, 
green, orange and purple bars respectively. The error-bars represent standard deviations from 
two independent experiments.  
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Fig. 3.23. Detection of multiple toxins in a multiplex assay 
Solutions containing a mixture of two or more toxins were tested in multiplex assays, at the 
indicated concentrations. Fluorescence emitted by each Vβ-immobilized bead due to toxin 
binding, was plotted on bar graphs shown. Fluorescence emitted by KKR (Vβ-SpeA), D10V (Vβ-
TSST-1), HGSM (Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown by red, 
blue, green, orange and purple bars respectively. The error-bars represent standard deviations 
from two independent experiments. 
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Fig. 3.24. Multiplex assay for toxin detection in culture supernatants of various strains of 
Staphylococcus aureus 
Supernatants (diluted 1:4) from cultures of 18 strains of Staphylococcus aureus obtained from the 
NARSA repository, were tested in a multiplex assay to determine their toxin expression profile. 
Median fluorescence units (in FL-1 and FL-4 channels) emitted by each Vβ-immobilized were 
analyzed on a scatter plot to determine the presence or absence of toxin(s), and identity of the 
toxin. Bar graphs indicating fluorescence in FL-4 channel (due to toxin binding) exhibited by each 
Vβ coated bead are shown. Fluorescence emitted by KKR (Vβ-SpeA), D10V (Vβ-TSST-1), HGSM 
(Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown by red, blue, green, orange 
and purple bars respectively. The error-bars represent standard deviations from two independent 
experiments.  
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Fig. 3.24 (cont.). Multiplex assay with supernatants from cultures of various strains of 
Staphylococcus aureus 
Supernatants (diluted 1:4) from cultures of 18 strains of Staphylococcus aureus obtained from the 
NARSA repository, were tested in a multiplex assay to determine their toxin expression profile. 
Median fluorescence units (in FL-1 and FL-4 channels) emitted by each Vβ-immobilized were 
analyzed on a scatter plot to determine the presence or absence of toxin(s), and identity of the 
toxin. Bar graphs indicating fluorescence in FL-4 channel (due to toxin binding) exhibited by each 
Vβ coated bead are shown. Fluorescence emitted by KKR (Vβ-SpeA), D10V (Vβ-TSST-1), HGSM 
(Vβ-SpeC), G5-8 (Vβ-SEB) and FL (Vβ-SEA) coated beads, is shown by red, blue, green, orange 
and purple bars respectively. The error-bars represent standard deviations from two independent 
experiments.  
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TABLES 
Table 3.1. Yield of high-affinity Vβ proteins as inclusion bodies, from E.coli 
High-affinity Vβ proteins were expressed as inclusion bodies in E.coli transformed with pET28a 
containing either thrombin cleavage site (T) between 6X His-tag and the Vβ sequence; or without 
thrombin cleavage site (NT) between 6X His-tag and the Vβ sequence. Cells were lysed using a 
microfluidizer and inclusion bodies were harvested. Yields (in g/l) are indicated. 
High-affinity 
Vβ protein 
Inclusion bodies 
prepared (g) 
Inclusion bodies harvested 
from E.coli culture (l) 
Yield 
(g/l) 
FL (T) 1.43 3 0.48 
D10V (T) 1.17 3 0.4 
G5-8 (NT) 0.32 1.5 0.21 
G5-8 (T) 1 3 0.33 
L3 (NT) 0.29 1.5 0.2 
L3 (T) 1.03 3 0.34 
HGSM (NT) 0.43 1.5 0.29 
KKR (NT) 0.74 1.5 0.5 
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Table 3.2. Comparison of sensitivities of toxin detection in capture ELISA versus a bead-
based, singleplex flow cytometry assay 
Toxin 
Sensitivity of detection 
Fold improvement in 
sensitivity in bead-
based, singleplex, flow 
cytometry assay 
Capture ELISA 
(ng/ml) 
Singleplex assay 
(Flow cytometry) 
(ng/ml) 
SEA 2.5-10 0.4 6.25-25 
SEB 0.25 0.003 83.33 
TSST-1 0.1-0.25 0.025 4-10 
SpeA 25-100 6.3 4-16 
SpeC 1-2.5 0.1 10-25 
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Table 3.3. Comparison of sensitivities of toxin detection in bead-based, singleplex versus 
multiplex flow cytometry assay 
Toxin 
Sensitivity of detection 
Fold decrease in 
sensitivity in multiplex 
set up 
Singleplex assay 
(Flow cytometry) 
(ng/ml) 
Multiplex assay 
(Flow cytometry) 
(ng/ml) 
SEA 0.4 10 25 
SEB 0.003 0.1 33.33 
TSST-1 0.025 0.1 4 
SpeA 6.3 10 ~ 1.6 
SpeC 0.1 1 10 
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Table 3.4. Summary of sources of Staphylococcus aureus strains analyzed 
Where available, information about presence or absence of SAg genes, and/or proteins, is shown. 
Also shown are the SAg expression profiles as determined by multiplex assay in the present work. 
Strain 
(NARSA 
nomenclature/
aliases) 
Source of isolatea Presence or absence 
of SEA, SEB, or 
TSST-1 gene(s) or 
protein(s), 
GenBankb/NARSAc/ 
other investigatorsd 
Presence of SAg 
determined by 
Multiplex assay 
SEA SEB TSST-1 
NRS1/ 
ATCC700699/ 
Mu50 
Pus and debrided tissue at 
surgical incision in 
sternum of 4 month-old 
infant, Japan 
SEA gene+ 
(GenBank); 
TSST-1 gene+ 
(GenBank) 
+  + 
NRS2/ 
ATCC700698 
Not reported Not reported +  + 
NRS22/ 
HIP07930/ 
USA600/99758 
Bloodstream of an adult 
female ICU patient, US 
SEA gene- (NARSA); 
SEB gene- (NARSA); 
TSST-1 gene- 
(NARSA) 
   
NRS70/ 
N315/USA100 
Pharyngeal smear of a 
patient, Japan 
TSST-1 gene+ 
(GenBank) 
  + 
NRS100/ 
COL 
Archaic methicillin 
resistant S.aureus (MRSA) 
strain, UK 
SEB gene+ (GenBank) 
 
 +  
NRS111/ 
TKI913/ 
FRI913 
Food associated with a 
staphylococcal food 
poisoning outbreak, US 
SEA gene+ (NARSA); 
TSST-1 gene+ 
(NARSA); 
SEA gene+ (PCR) 
[151]; 
TSST-1 gene+ (PCR) 
[151]; 
+  + 
NRS112/ 
MN8 
Patient with menstrual 
TSS, US 
SEA gene+ (PCR) 
[150]; 
TSST-1+ [150]; 
+  + 
NRS113/ 
MNDON 
Not reported Not reported  +  
NRS114/ 
MNHOCH 
Not reported SEB gene+ (PCR) 
[151]; 
 +  
NRS382/ 
USA100 
Bloodstream sample, US Not reported    
NRS382/ 
USA100 
Bloodstream sample, US Not reported    
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Table 3.4 (cont.). Summary of sources of Staphylococcus aureus strains analyzed 
Where available, information about presence or absence of SAg genes, and/or proteins, is shown. 
Also shown are the SAg expression profiles as determined by multiplex assay in the present work. 
 
Strain 
(NARSA 
nomenclature/
aliases) 
Source of isolatea Presence or absence 
of SEA, SEB, or 
TSST-1 gene(s) or 
protein(s), 
GenBankb/NARSAc/ 
other investigatorsd 
Presence of SAg 
determined by 
Multiplex assay 
SEA SEB TSST-1 
NRS384/ 
USA300 
Isolated from wound, US Not reported    
NRS387/ 
USA800 
Isolated from wound, US SEB gene+ (NARSA) 
 
 +  
NRS651/ 
CA-409 
Isolated from peritoneal 
fluid, US 
TSST-1 gene+ 
(NARSA) 
 
+  + 
NRS667/ 
CO-71 
Not reported Not reported    
NRS695 Not reported Not reported +   
NRS701/ 
MN-082 
Not reported Not reported   + 
NRS725/ 
OR-25 
Not reported Not reported    
NRS741/ 
TN90 
Not reported Not reported    
 
 
aSources of the isolates were described by NARSA or ATCC (American Type Culture 
Collection). 
bInformation about presence or absence of SAg genes was obtained by performing BLAST 
analysis on genome sequences available in GenBank (NIH genetic sequence database). 
cInformation about presence or absence of SAg genes was obtained as annotations from 
NARSA website. 
dInformation about presence or absence of SAg genes was established by other investigators 
(references indicated). 
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Table 3.5. Estimated concentrations of SEA, SEB and TSST-1 in the supernatants of 
various Staphylococcus aureus strains, by linear or nonlinear regression methods 
Staphylococcus 
aureus strain 
Concentration of toxins estimated by multiplex 
assay 
SEA (ng/ml) SEB (ng/ml) 
TSST-1 
(ng/ml) 
NRS1 
611 ± 111 
(>400 ng/ml**) 
 41 ± 4 
NRS2 
500 ± 30 
(>400 ng/ml**) 
 36 ± 6 
NRS22    
NRS70   25 ± 6 
NRS100  271 ± 78**  
NRS111 116 ± 44  115 ± 24** 
NRS112 175 ± 54  119 ± 27** 
NRS113  9.2 ± 3  
NRS114  270 ± 65**  
NRS382    
NRS384    
NRS387  286 ±103**  
NRS651 85 ± 26  25 ± 5 
NRS667    
NRS695 82 ± 1   
NRS701   36 ± 6 
NRS725    
NRS741    
Sensitivity of toxin 
detection (ng/ml) 
10 0.1 0.1 
** MFU values for these strains were outside the linear range, hence 
concentrations were approximated by non-linear regression. 
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Table 3.6. Comparison of sensitivities of toxin detection by different assays and the KD of 
Vβ: toxin interaction. 
Toxin 
Sensitivity of detection 
K
D
 
(Vβ:toxin) 
(nM) 
Capture 
ELISA 
(ng/ml) 
Singleplex assay 
(Flow cytometry) 
(ng/ml) 
Multiplex assay 
(Flow cytometry)  
(ng/ml) 
SEA 2.5-10 0.4 10 4 
SEB 0.25 0.003 0.1 0.05 
TSST-1 0.1-0.25 0.025 0.1 0.05 
SpeA 25-100 6.3 10 0.27 
SpeC 1-2.5 0.1 1 0.5 
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